Derivation of immediately dangerous to life or health (IDLH) values by Dotson, G. Scott et al.
Derivation of Immediately Dangerous 
to Life or Health (IDLH) Values
CURRENT  INTELLIGENCE  BULLETIN  66
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
Centers for Disease Control and Prevention 
National Institute for Occupational Safety and Health
Cover photo: Courtesy of Dupont
Derivation of Immediately Dangerous 
to Life or Health (IDLH)Values
Current Intelligence Bulletin 66
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
Centers for Disease Control and Prevention 
National Institute for Occupational Safety and Health
ii NIOSH CIB 66 • Derivation of Immediately Dangerous to Life or Health (IDLH) Values
This document is in the public domain and may be freely copied or reprinted.
Disclaimer
Mention of any company or product does not constitute endorsement by the National In-
stitute for Occupational Safety and Health (NIOSH). In addition, citations to websites ex-
ternal to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations 
or their programs or products. Furthermore, NIOSH is not responsible for the content of 
these websites. All Web addresses referenced in this document were accessible as of the 
publication date.
Ordering Information
To receive documents or other information about occupational safety and health topics, 
contact NIOSH:
Telephone: 1–800–CDC–INFO (1–800–232–4636) 
TTY: 1–888–232–6348 
CDC INFO: www.cdc.gov/info
or visit the NIOSH website at www.cdc.gov/niosh.
For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting  
www.cdc.gov/niosh/eNews.
Suggested Citation
NIOSH [2013]. Current intelligence bulletin 66: derivation of immediately dangerous to life 
or health (IDLH) values. Cincinnati, OH: US Department of Health and Human Services, 
Centers for Disease Control and Prevention, National Institute for Occupational Safety and 
Health, DHHS (NIOSH) Publication 2014–100.
DHHS (NIOSH) Publication No. 2014–100
November 2013
Safer • Healthier • PeopleTM
iiiNIOSH CIB 66 • Derivation of Immediately Dangerous to Life or Health (IDLH) Values
Foreword
Since the establishment of the original Immediately Dangerous to Life or Health (IDLH) val-
ues in 1974, the National Institute for Occupational Safety and Health (NIOSH) has con-
tinued to review available scientific data to improve the methodology used to derive acute 
exposure guidelines, in addition to the chemical-specific IDLH values. The primary objective 
of this Current Intelligence Bulletin (CIB) is to present a methodology, based on the modern 
principles of risk assessment and toxicology, for the derivation of IDLH values, which charac-
terize the health risks of occupational exposures to high concentrations of airborne contami-
nants. The methodology for deriving IDLH values presented in the CIB incorporates the ap-
proach established by the National Advisory Committee on Acute Exposure Guideline Levels 
(AEGLs) for Hazardous Substances—consisting of members from the U.S. Environmental 
Protection Agency, U.S. Department of Defense, U.S. Department of Energy, U.S. Depart-
ment of Transportation, other federal and state government agencies, the chemical industry, 
academia, labor, and other organizations from the private sector—during the derivation of 
community-based acute exposure limits. The inclusion of the AEGL methodology has helped 
ensure that the IDLH values derived with use of the guidance provided in this document are 
based on validated scientific rationale.
The intent of this document is not only to update the IDLH methodology used by NIOSH 
to develop IDLH values based on contemporary risk assessment practices, but also to in-
crease the transparency behind their derivation. The increased transparency will provide 
occupational health professionals, risk managers, and emergency response personnel ad-
ditional information that can be applied to improve characterization of the hazards of 
high concentrations of airborne contaminants. This will also facilitate a more informed 
decision-making process for the selection of respirators and establishment of risk man-
agement plans for non-routine work practices and emergency preparedness plans capable 
of better protecting workers. 
John Howard, M.D. 
Director, National Institute for Occupational  
   Safety and Health  
Centers for Disease Control and Prevention
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Executive Summary
Chemicals are a ubiquitous component of the modern workplace. Occupational exposures 
to chemicals have long been recognized as having the potential to adversely affect the lives 
and health of workers. Acute or short-term exposures to high concentrations of some air-
borne chemicals have the ability to quickly overwhelm workers, resulting in a spectrum 
of undesirable outcomes that may include irritation of the eyes and respiratory tract, se-
vere irreversible health effects, impairment of the ability to escape from the exposure en-
vironment, and, in extreme cases, death. Airborne concentrations of chemicals capable of 
causing such adverse health effects or of impeding escape from high-risk conditions may 
arise from a variety of non-routine workplace situations affecting workers, including special 
work procedures (e.g., in confined spaces), industrial accidents (e.g., chemical spills or ex-
plosions), and chemical releases into the community (e.g., during transportation incidents 
or other uncontrolled-release scenarios). 
Since the 1970s, the National Institute for Occupational Safety and Health (NIOSH) has been 
responsible for the development of acute exposure guidelines called Immediately Danger-
ous to Life or Health (IDLH) values, which are intended to characterize these high-risk con-
ditions. Used initially as key components of the NIOSH Respirator Selection Logic [NIOSH 
2004], IDLH values are established (1) to ensure that the worker can escape from a given con-
taminated environment in the event of failure of the respiratory protection equipment and (2) 
to indicate a maximum level above which only a highly reliable breathing apparatus, provid-
ing maximum worker protection, is permitted. In addition, occupational health professionals 
have employed these acute exposure guidelines beyond their initial purpose as a component 
of the NIOSH Respirator Selection Logic. Examples of such applications of the IDLH values 
include the development of Risk Management Plans (RMPs) for non-routine work practices 
governing operations in high-risk environments (e.g., confined spaces) and the development 
of Emergency Preparedness Plans (EPPs), which provide guidance for emergency response 
personnel and workers during unplanned exposure events. 
Since the establishment of the IDLH values in the 1970s, NIOSH has continued to review 
available scientific data to improve the protocol used to derive acute exposure guidelines, 
in addition to the chemical-specific IDLH values. The information presented in this Cur-
rent Intelligence Bulletin (CIB) represents the most recent update of the scientific rationale 
and the methodology (hereby referred to as the IDLH methodology) used to derive IDLH 
values. The primary objectives of this document are to
 • Provide a brief history of the development of IDLH values 
 • Update the scientific bases and risk assessment methodology used to derive IDLH 
values from quality data
 • Provide transparency behind the rationale and derivation process for IDLH values
 • Demonstrate how scientifically credible IDLH values can be derived from available 
data resources.
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The IDLH methodology outlined in this CIB reflects the modern principles and under-
standing in the fields of risk assessment, toxicology, and occupational health and provides 
the scientific rationale for the derivation of IDLH values based on contemporary risk as-
sessment practices. According to this protocol, IDLH values are based on health effects con-
siderations determined through a critical assessment of the toxicology and human health 
effects data. This approach ensures that the IDLH values reflect an airborne concentration 
of a substance that represents a high-risk situation that may endanger workers’ lives or 
health. Relevant airborne concentrations are typically addressed through the characteriza-
tion of inhalation exposures; however, airborne chemicals can also contribute to toxicity 
through other exposure routes, such as the skin and eyes. In this document, airborne con-
centrations are referred to as acute inhalation limits or guidelines to adhere to commonly 
used nomenclature. 
The emphasis on health effects is consistent with both the traditional use of IDLH values as 
a component of the respirator selection logic and the growing applications of IDLH values 
in RMPs for non-routine work practices governing operations in high-risk environments 
(e.g., confined spaces) and the development of EPPs. Incorporated in the IDLH methodol-
ogy are the standing guidelines and procedures [NAS 2001] used for the development of 
community-based acute exposure limits called Acute Exposure Guideline Levels (AEGLs). 
The inclusion of the AEGL methodology has helped ensure that the health-based IDLH 
values derived with use of the guidance provided in this document are based on validated 
scientific rationale. 
The IDLH methodology is based on a weight-of-evidence approach that applies scientific 
judgment for critical evaluation of the quality and consistency of scientific data and in ex-
trapolation from the available data to the IDLH value. The weight-of-evidence approach 
refers to critical examination of all available data from diverse lines of evidence and the 
derivation of a scientific interpretation on the basis of the collective body of data, includ-
ing its relevance, quality, and reported results. This is in contrast to a purely hierarchical or 
strength-of-evidence approach, which relies on rigid decision criteria for selecting a critical 
adverse effect, a point of departure (POD), or the point on the dose–response curve from 
which dose extrapolation is initiated and for applying default uncertainty factors (UFs) to 
derive the IDLH value. Conceptually, the derivation process for IDLH values is similar to 
that used in other risk-assessment applications, including these steps:
 • Hazard characterization 
 • Identification of critical adverse effects 
 • Identification of a POD 
 • Application of appropriate UFs, based on the study and POD 
 • Determination of the final risk value. 
However, the use of a weight-of-evidence approach allows for integration of all avail-
able data that may originate from different lines of evidence into the analysis and the 
subsequent derivation of an IDLH value. Ideally, this ensures that the analysis is not 
restricted to a limited dataset or a single study for a specific chemical. In particular, 
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application of the appropriate UFs to each potential POD allows for consideration of 
the impact of the overall dataset as well as the uncertainties associated with each po-
tential key study in determining the final IDLH value. 
The primary steps (see Figure 3–1) applied in the establishment of an IDLH value include 
the following:
 • Critical review of human and animal toxicity data to identify potential relevant stud-
ies and characterize the various lines of evidence that can support the derivation of 
the IDLH value 
 • Determination of a chemical’s mode of action (MOA) or description of how a chemi-
cal exerts its toxic effects 
 • Application of duration adjustments (time scaling) to determine 30-minute-equivalent 
exposure concentrations and the conduct of other dosimetry adjustments, as needed 
 • Selection and application of a UF for POD or critical adverse effect concentration, 
identified from the available studies to account for issues associated with interspe-
cies and intraspecies differences, severity of the observed effects, data quality, or data 
insufficiencies 
 • Development of the final recommendation for the IDLH value from the various alter-
native lines of evidence, with use of a weight-of-evidence approach to all of the data.
NIOSH recognizes that in some cases a health-based IDLH value might not account for all 
workplace hazards, such as safety concerns or considerations. Here are some examples of 
situations and conditions that might preclude the use of a health-based IDLH value: 
 • The airborne concentration of a substance is sufficient to cause oxygen deprivation 
(oxygen concentration <19.5%), a life-threatening condition
 • The concentration of particulate matter generated during a process significantly re-
duces visibility, preventing escape from the hazardous environment 
 • The airborne concentration of a gas or vapor is greater than 10% of the lower explo-
sive limit (LEL) and represents an explosive hazard.
In such cases, it is important that safety hazards or other considerations be taken into ac-
count. Information on the safety hazards will be incorporated in the support documenta-
tion (see Appendix A) for an IDLH value, to aid occupational health professionals in the 
development of RMPs for non-routine work practices governing operations in high-risk 
environments (e.g., confined spaces) and EPPs. In the event that the derived health-based 
IDLH value exceeds 10% of the LEL concentration for a flammable gas or vapor, the air 
concentration that is equal to 10% of the LEL will become the default IDLH value for the 
chemical. The following hazard statement will be included in the support documentation: 
“The health-based IDLH value is greater than 10% of the LEL (>10% LEL) of the chemical 
of interest in the air. Safety considerations related to the potential hazard of explosion must 
be taken into account.” In addition, the notation “>10% LEL” will appear beside the IDLH 
value in the NIOSH Pocket Guide to Chemical Hazards [NIOSH 2005] and other NIOSH 
publications. The equivalent default approach for dust would be based on 10% of the mini-
mum explosive concentration (MEC).  However, determining the  combustibility of dusts is 
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complicated and dictated by the relationship between multiple dust-specific factors includ-
ing, but not limited to, particle size distribution, minimum ignition energy, explosion in-
tensity, and dispersal in the air [Cashdollar 2000]. The ability to quantify dust-specific con-
centrations that could represent explosive hazards for risk assessment purposes is limited 
and often not possible given the absence of critical data, such as chemical-specific MEC and 
other previously identified factors. Despite the absence of specific guidance, NIOSH will 
critically assess  the explosive nature of a dust when sufficient technical data are available. 
If determined to be appropriate, the findings of this assessment will be incorporated into 
the derivation process to ensure that the IDLH value is protective against both health and 
safety hazards. When an explosive hazard is identified for an aerosol, NIOSH will include 
the following hazard statement: “Dust may represent an explosive hazard. Safety consider-
ations related to hazard of explosion must be taken into account.” In addition, the notation 
(Combustible Dust) will appear in other NIOSH publications. 
Supplemental information is included in this CIB to provide insight into (1) the literature 
search strategy, (2) the scheme used to prioritize and select chemicals for which an IDLH value 
will be established, and (3) an overview of the analysis applied by NIOSH to develop a scientifi-
cally based approach for the selection of the UF during the derivation of IDLH values. In addi-
tion, Appendix A presents an example of the derivation of an IDLH value for chlorine (CAS# 
7782-50-5), based on the scientific rationale and process outlined in this CIB. The example 
highlights the primary steps in establishment of an IDLH value, including a critical review 
of the identified human and animal data, discussion of the selection of the POD and UF, and 
extrapolation of the 30-minute-equivalent exposure concentration from animal toxicity data.
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Glossary*
Acute Exposure: Exposure by the oral, dermal, or inhalation route for 24 hours or less.
Acute Exposure Guideline Levels (AEGLs): Threshold exposure limits for the general 
public applicable to emergency exposure periods ranging from 10 minutes to 8 hours. 
AEGL-1, AEGL 2, and AEGL-3 are developed for five exposure periods (10 and 30 min-
utes, 1 hour, 4 hours, and 8 hours) and are distinguished by varying degrees of sever-
ity of toxic effects ranging from transient, reversible effects to life-threatening effects 
[NAS 2001]. AEGLs are intended to be guideline levels used during rare events or single 
once-in-a-lifetime exposures to airborne concentrations of acutely toxic, high-priority 
chemicals [NAS 2001].  The threshold exposure limits are designed to protect the general 
population, including the elderly, children or other potentially sensitive groups that are 
generally not considered in the development of workplace exposure recommendations 
(additional information available at http://www.epa.gov/oppt/aegl/).
Acute Reference Concentration (RfC): An estimate (with uncertainty spanning perhaps 
an order of magnitude) of a continuous inhalation exposure for an acute duration (24 
hours or less) of the human population (including sensitive subgroups) that is likely to be 
without an appreciable risk of deleterious effects during a lifetime. It can be derived from 
a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors (UFs) generally 
applied to reflect limitations of the data used. Generally used in USEPA noncancer health 
assessments [USEPA 2010]. 
Acute Toxicity: Any poisonous effect produced within a short period of time following 
an exposure, usually 24 to 96 hours.
Acute Toxicity Test: Experimental animal study to determine what adverse effects occur in 
a short time (usually up to 14 days) after a single dose of a chemical or after multiple doses 
given in up to 24 hours.
Adverse Effect: A substance-related biochemical change, functional impairment, or 
pathologic lesion that affects the performance of an organ or system or alters the ability 
to respond to additional environmental challenges. 
Analytical (Actual) Concentration: The test article concentration to which animals are 
exposed (i.e., the concentration in the animals’ breathing zone), as measured by analytical 
(GC, HPLC, etc.) or gravimetric methods. The analytical or gravimetric concentration (not 
the nominal concentration) is usually used for concentration response assessment.
Assigned Protection Factor (APF): The minimum anticipated protection provided by a 
properly functioning respirator or class of respirators to a given percentage of properly 
*Except where specific references are given, glossary definitions are from numerous sources such as AIHA 
[2008], Hayes [2008], IUPAC [2007], NAS [1986, 2001], NASA [1999], NIOSH [2005], OSHA [2003], 
US DHS [2007], US DOE [2008], and US DOT [2008].
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fitted and trained users. For example, an APF of 10 for a respirator means that a user could 
expect to inhale no more than one tenth of the airborne contaminant present.
Benchmark Dose/Concentration (BMD/BMC): A dose or concentration that produces 
a predetermined change in response rate of an effect (called the benchmark response, 
or BMR) compared to background [USEPA 2010] (additional information available at 
http://www.epa.gov/ncea/bmds/). 
Benchmark Response (BMR): A predetermined change in response rate of an effect. Com-
mon defaults for the BMR are 10% or 5%, reflecting study design, data variability, and sen-
sitivity limits used.
BMCL: A statistical lower confidence limit on the concentration at the BMC [USEPA 2010].
Biologically Based Dose Response (BBDR) model: A predictive model that describes 
biological processes at the cellular and molecular level, linking the target organ dose to the 
adverse effect [USEPA 2010].
Bolus Exposure: A single, relatively large dose. 
Bounding: A process of identifying estimates of exposure, dose, or risk that are clearly 
higher than or lower than the exposure, dose, or risk of interest. Bounding can help to de-
fine the practical uncertainty associated with the estimate of a derived risk value, such as 
an IDLH value. 
Cancer Risk: The likelihood of developing cancer, given a specific exposure (i.e., during a 
working lifetime). Individual cancer risks are determined by multiplying a specific expo-
sure by the cancer potency. A 10-3 risk level is often characterized as a 1 in 1,000 chance of 
developing cancer in occupational risk assessment.
Carcinogen: An agent capable of causing cancer.
Carcinogenicity: Process of induction of malignant tumors by chemical, physical, or bio-
logical agents.
Ceiling Value (“C”): U.S. term in occupational exposure indicating the airborne concen-
tration of a potentially toxic substance that should never be exceeded in a worker’s breath-
ing zone.
Chronic Exposure: Repeated exposure for an extended period of time. Typically expo-
sures are more than approximately 10% of life span for humans and >90 days to 2 years for 
laboratory species.
Concentration (Conc): The mass of test article per unit volume of air (e.g., mg/L, mg/m3) 
or the volume of test article per unit volume (e.g., ppm, mL/L).
Concentration-response Curve: Graph of the relationship between the exposure concen-
tration and the incidence or other measure of response of a defined biological effect in an 
exposed population or animal study.
Critical Study: The study that contributes most significantly to the qualitative and quantita-
tive assessment of risk [USEPA 2010].
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Cumulative Toxicity: Toxicity that is related to the cumulative, or total, dose to an organ or 
the body of an individual, up to a specified date or time. 
Developmental Toxicity: Adverse effects on the developing organism that may result from 
exposure prior to conception (either parent), during prenatal development, or postnatally 
until the time of sexual maturation [USEPA 2010]. The major manifestations of develop-
mental toxicity include death of the developing organism, structural abnormality, altered 
growth, and functional deficiency.
De Novo: Referring to an analysis that does not build on prior analyses.
Dose: The amount of a substance available for interactions with metabolic processes 
or biologically significant receptors after crossing the outer boundary of an organism 
[USEPA 2010].
Dosimetry: Estimating or measuring the quantity of material at specific target sites; deter-
mination of respiratory tract region deposition fractions. 
ECt50: A combination of the effective concentration of a substance in the air and the ex-
posure duration that is predicted to cause an effect in 50% (one half) of the experimental 
test subjects.
Emergency and Continuous Exposure Guidance Level (EEGL): A ceiling guidance level 
for unpredicted, single, short-term, emergency exposures (1 to 24 hours) of a defined oc-
cupational group. EEGLs are developed at the request of the U.S. Department of Defense by 
the National Research Council’s Committee on Toxicology [NAS 1996, 2008]. 
Emergency Response Planning Guidelines (ERPGs): Maximum airborne concentra-
tions below which nearly all individuals can be exposed without experiencing health ef-
fects for 1-hour exposure. ERPGs are presented in a tiered fashion with health effects 
ranging from mild or transient to serious, irreversible, or life threatening (depending 
on the tier). ERPGs are developed by the American Industrial Hygiene Association 
[AIHA 2006].
Endpoint: An observable or measurable biological event or sign of toxicity ranging from 
biomarkers of initial response to gross manifestations of clinical toxicity.
Exposure: Contact made between a chemical, physical, or biological agent and the outer 
boundary of an organism. Exposure is quantified as the amount of an agent available at the 
exchange boundaries of the organism (e.g., skin, lungs, gut).
Extrapolation: An estimate of the response at a point outside the range of the experimental 
data, generally through the use of a mathematical model, although qualitative extrapolation 
may also be conducted. The model may then be used to extrapolate to response levels that 
cannot be directly observed.
Fetal Toxicity: An adverse effect occurring in the fetus from exposure to a substance. These 
effects can occur through direct interaction with the fetus or indirectly from the effects of 
maternal toxicity.
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Gestation: Pregnancy, the period of development in the uterus from conception until birth.
Hazard: A potential source of harm. Hazard is distinguished from risk, which is the prob-
ability of harm under specific exposure conditions.
Healthy Worker Effect: Epidemiological phenomenon observed initially in studies 
of occupational diseases: workers usually exhibit lower overall disease and death rates 
than the general population, due to the fact that elderly individuals and those with 
significant pre-existing illness are less likely to be active in the workforce than healthy 
adults. Death rates in the general population may be inappropriate for comparison with 
occupational death rates, if this effect is not taken into account.
Immediately Dangerous to Life or Health (IDLH) condition: A situation that poses a 
threat of exposure to airborne contaminants when that exposure is likely to cause death 
or immediate or delayed permanent adverse health effects or prevent escape from such 
an environment [NIOSH 2004]. 
IDLH value: A maximum (airborne concentration) level above which only a highly reliable 
breathing apparatus providing maximum worker protection is permitted [NIOSH 2004]. 
IDLH values are based on a 30-minute exposure duration.
Implantation: The process by which a fertilized egg implants in the uterine lining, typically 
several days following conception, depending on the species.
Inhalation Reference Concentration (RfC): An estimate (with uncertainty spanning 
perhaps an order of magnitude) of a continuous inhalation exposure for a chronic dura-
tion (up to a lifetime) of the human population (including sensitive subgroups) that is 
likely to be without an appreciable risk of deleterious effects during a lifetime [USEPA 
2010]. It can be derived from a NOAEL, LOAEL, or benchmark concentration, with UF 
generally applied to reflect limitations of the data used. Generally used in USEPA non-
cancer health assessments.
Internal Dose: A dose denoting the amount absorbed without respect to specific absorp-
tion barriers or exchange boundaries.
International Toxicity Estimates for Risk Database (ITER): A free Internet database of 
human health risk values and cancer classifications for over 600 chemicals of environmen-
tal concern, from multiple organizations worldwide (additional information available at 
http://www.tera.org/iter/).
Intraperitoneal: Within the peritoneal cavity (the area that contains the abdominal organs).
LC01: The statistically determined concentration of a substance in the air that is estimated to 
cause death in 1% of the test animals.
LC50: The statistically determined concentration of a substance in the air that is estimated to 
cause death in 50% (one half) of the test animals; median lethal concentration.
LCLO: The lowest lethal concentration of a substance in the air reported to cause death, usu-
ally for a small percentage of the test animals.
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LD50: The statistically determined lethal dose of a substance that is estimated to cause death 
in 50% (one half) of the test animals; median lethal concentration.
LDLO: The lowest dose of a substance that causes death, usually for a small percentage of the 
test animals.
LEL: The minimum concentration of a gas or vapor in air, below which propagation of a 
flame does not occur in the presence of an ignition source.
Lethality: Pertaining to or causing death; fatal; referring to the deaths resulting from acute 
toxicity studies. May also be used in lethality threshold to describe the point of sufficient 
substance concentration to begin to cause death.
Lowest Observed Adverse Effect Level (LOAEL): the lowest tested dose or concentra-
tion of a substance that has been reported to cause harmful (adverse) health effects in 
people or animals. 
Malignant: A growth with a tendency to invade and destroy nearby tissue and spread to 
other parts of the body.
Maternal Toxicity: Adverse effects occurring in the mother during a developmental study. 
Maternal toxicity can result in adverse effects to the fetus.
Maximum Likelihood Concentration: A statistical estimate of the concentration that was 
most likely to cause the desired effect.
Mode of Action: The sequence of significant events and processes that describe how a sub-
stance causes a toxic outcome. Mode of action is distinguished from the more detailed 
mechanism of action, which implies a more detailed understanding on a molecular level.
Nominal Concentration: The concentration of test article introduced into a chamber. It is 
calculated by dividing the mass of test article generated by the volume of air passed through 
the chamber. The nominal concentration does not necessarily reflect the concentration to 
which an animal is exposed. 
No Observed Adverse Effect Level (NOAEL): The highest tested dose or concentration of 
a substance that has been reported to cause no harmful (adverse) health effects in people 
or animals. 
Occupational Exposure Limit (OEL): Workplace exposure recommendations developed 
by governmental agencies and non-govermental organizations. OELs are intended to repre-
sent the maximum airborne concentrations of a chemical substance below which workplace 
exposures should not cause adverse health effects. OELs may apply to ceiling, short-term 
(STELs), or time-weighted average (TWA) limits.
Parturition: The act or process of giving birth.
Peak Concentration: Highest concentration of a substance recorded during a certain pe-
riod of observation.
Permissible Exposure Limit (PEL): Occupational exposure limits developed by OSHA (29 
CFR 1910.1000) or MSHA (30 CFR 57.5001) for allowable occupational airborne exposure 
concentrations. PELs are legally enforceable and may be designated as ceiling, STEL, or 
TWA limits. 
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Permit-Required Confined Spaces: OSHA defines a confined space as one that has one or 
more of the following characteristics: (1) contains or has the potential to contain a hazard-
ous atmosphere; (2) contains a material that has the potential to engulf an entrant; (3) has 
walls that converge inward or floors that slope downward and taper into a smaller area 
which could trap or asphyxiate an entrant; (4) or contains any other recognized safety or 
health hazard, such as unguarded machinery, exposed live wires, or heat stress.
Physiologically Based Pharmacokinetic (PBPK) Model: A model that estimates the dose 
to a target tissue or organ by taking into account the rate of absorption into the body, distri-
bution among target organs and tissues, metabolism, and excretion. 
Point of Departure (POD): The point on the dose–response curve from which dose ex-
trapolation is initiated. This point can be the lower bound on dose for an estimated inci-
dence or a change in response level from a concentration-response model (BMC), or it can 
be a NOAEL or LOAEL for an observed effect selected from a dose evaluated in a health 
effects or toxicology study. 
Promulgation: To make known (a decree, for example) by public declaration; 
announce officially.
Provisional Advisory Level (PAL): A tiered set of air and drinking water threshold expo-
sure values for high priority chemical, biological, and radiological agents intended for the 
general public, including susceptible and sensitive subpopulations. Developed by USEPA to 
inform risk-based decision-making during a response to terrorist or natural disaster inci-
dents [US DHS 2009].
RD50: The statistically determined concentration of a substance in the air that is estimated 
to cause a 50% (one half) decrease in the respiratory rate.
Recommended Exposure Limit (REL): Recommended maximum exposure limit to pre-
vent adverse health effects based on human and animal studies and established for occu-
pational (up to 10-hour shift, 40-hour week) inhalation exposure by NIOSH. RELs may be 
designated as ceiling, STEL, or TWA limits.
Reproductive Toxicology: The study of adverse effects on male and/or female reproduc-
tive function, capacity, or associated endocrine system components. Common adverse 
effects include altered sexual behavior, fertility, pregnancy outcomes, or modifications 
in other functions that depend on reproductive integrity of the system.
Risk Phrases: A European system of hazard codes and phrases for labeling dangerous sub-
stances and compounds, consisting of the letter R followed by a series of numbers. Each 
number corresponds to a specific hazard phrase. For example, R-34 means “causes burns,” 
regardless of any language translations.
Sensory Irritation: Immediate irritation to the eyes and nose, due to an interaction be-
tween the substance and receptors in the trigeminal nerve endings. Often an endpoint for 
OEL derivation.
Short-Term Exposure: Repeated exposure by the oral, dermal, or inhalation route for more 
than 24 hours, up to 30 days.
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Short-Term Exposure Limit (STEL): A worker’s 15-minute time-weighted average expo-
sure concentration that shall not be exceeded at any time during a work day.
Short-Term Public Emergency Guidance Level (SPEGL): A ceiling guidance level for un-
predicted, single, short-term, emergency exposures (1 to 24 hours) for the general public. 
SPEGLs are developed at the request of the U.S. Department of Defense by the National 
Research Council’s Committee on Toxicology [NAS 1986]. 
Spacecraft Maximum Allowable Concentration (SMAC): Guideline values set to protect 
astronauts from spacecraft contaminants. Short-term guidelines (1 to 24 hours) apply to ac-
cidental releases, and long-term guidelines (up to 180 days) apply to low levels of contami-
nants aboard a spacecraft. These guidelines are set by the NASA/JSC in cooperation with 
the National Research Council’s Committee on Toxicology [NASA 1999]. 
Surrogate: Relatively well studied chemical whose properties are assumed, with appropri-
ate adjustments for differences in potency, to apply to an entire chemically and toxicologi-
cally related class; for example, benzo(a)pyrene data are assumed to be toxicologically 
equivalent to those for all carcinogenic polynuclear aromatic hydrocarbons or are used 
as a basis for extrapolating to these other chemicals.
Systemic Concentration: The concentration in a blood or tissue arising from exposure to 
a substance that is absorbed and distributed throughout the body. 
Target Organ: Organ in which the toxic injury manifests in terms of dysfunction or overt 
disease.
Temporary Emergency Exposure Limits (TEELs): Tiered temporary guidance values 
that are used by DOE until AEGL or ERPG values are available. TEELs are derived by the 
Subcommittee on Consequence Assessment and Protective Actions (SCAPA) to aid in 
emergency preparedness hazard analysis of DOE facilities, employees, and adjacent com-
munities in the event of an accidental chemical release [US DOE 2008].
Threshold Limit Values (TLVs®): Recommended guidelines for occupational exposure to 
airborne contaminants, published by the American Conference of Governmental Indus-
trial Hygienists (ACGIH). TLVs refer to airborne concentrations of chemical substances 
and represent conditions under which it is believed that nearly all workers may be repeat-
edly exposed, day after day, over a working lifetime, without adverse effects. TLVs may be 
designated as ceiling, short-term (STELs), or 8-hr TWA limits. 
Time-Weighted Average (TWA): A worker’s 8-hour (or up to 10-hour) time-weighted aver-
age exposure concentration that shall not be exceeded during an 8-hour (or up to 10-hour) 
work shift of a 40-hour week. The average concentration is weighted to take into account the 
duration of different exposure concentrations. 
Toxic Inhalation Hazard (TIH): Gases or volatile liquids that are known or presumed on 
the basis of tests to be so toxic to humans as to pose a hazard to health in the event of a 
release during transportation, determined by DOT.
Toxicity: The degree to which a substance is able to cause an adverse effect on an ex-
posed organism.
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Toxicology: Scientific discipline involving the study of the actual or potential danger pre-
sented by the harmful effects of substances (poisons) on living organisms and ecosystems, 
of the relationship of such harmful effects to exposure, and of the mechanisms of action, 
diagnosis, prevention, and treatment of intoxications.
Tumor: An abnormal mass of tissue that results from excessive cell division that is uncon-
trolled and progressive. Tumors perform no useful body function. Tumors can be either 
benign (not cancerous) or malignant (cancerous).
Uncertainty Factors: Mathematical adjustments applied to the POD when developing 
IDLH values. The UFs for IDLH value derivation are determined by considering the study 
and effect used for the POD, with further modification based on the overall database.
Weight of Evidence (Toxicity): Extent to which the available biomedical data support a 
conclusion, such as whether a substance causes a defined toxic effect (e.g., cancer in hu-
mans), or whether an effect occurs at a specific exposure level.
Workplace Environmental Exposure Levels (WEELs): Exposure levels that provide guid-
ance for protecting most workers from adverse health effects related to occupational chemi-
cal exposures expressed as a TWA or ceiling limit.
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1 Introduction 
Occupational exposures to chemicals have long 
been recognized as having the potential to ad-
versely affect the lives and health of workers. Acute 
or short-term exposures to high concentrations of 
some airborne chemicals have the ability to quickly 
overwhelm workers, resulting in a wide spectrum 
of undesirable health outcomes that may include 
irritation of the eyes and respiratory tract, severe 
irreversible health effects, impairment of the ability 
to escape from the exposure environment, and, in 
extreme cases, death. Airborne concentrations of 
chemicals capable of causing such adverse health 
effects or impeding escape from “high risk” situ-
ations or conditions may arise from a variety of 
situations affecting workers, including special work 
procedures (e.g., in confined spaces), industrial 
accidents (e.g., chemical spills or explosions), or 
chemical releases into the community (e.g., during 
transportation incidents or other uncontrolled re-
lease scenarios). Many organizations develop acute 
inhalation limits or guidelines. These are typically 
presented as airborne concentrations. However, 
airborne chemicals can also contribute to toxicity 
through other exposure routes, such as the skin 
and eyes. 
The “immediately dangerous to life or health air 
concentration values (IDLH values)” developed by 
the National Institute for Occupational Safety and 
Health (NIOSH) characterize these high-risk ex-
posure concentrations and conditions and are used 
as a component of the respirator selection criteria 
first developed in the mid-1970s [NIOSH 1994]. 
Since the development of the original IDLH values 
in the 1970s and their subsequent revision in 1994, 
NIOSH has continued to review relevant scientific 
data and conduct research on methods for develop-
ing acute exposure guidelines. This document re-
flects continuing enhancements in risk assessment 
approaches and provides a detailed description of 
the methodology used to derive IDLH values. The 
documentation for specific IDLH values is avail-
able as separate NIOSH publications and on the 
NIOSH website (http://www.cdc.gov/niosh/idlh/
default.html).
The primary objectives of this Current Intelligence 
Bulletin (CIB) are:
1. To provide a brief history of the development of 
IDLH values, 
2. To update the scientific bases and risk assessment 
methodology used to derive IDLH values from 
quality toxicity and human health effects data,
3. To provide transparency behind the rationale 
and derivation process for IDLH values, and
4. To demonstrate how scientifically credible IDLH 
values can be derived from available data resources.
1.1  Background 
The concept of using respirators to protect work-
ers in situations that are immediately dangerous to 
life or health was discussed at least as early as the 
1940s. The following is from a 1944 U.S. Depart-
ment of Labor (DOL) bulletin:
The situations for which respiratory protec-
tion is required may be designated as, (1) non-
emergency and (2) emergency. Nonemergency 
situations are the more or less normal ones that 
involve exposure to atmospheres that are not 
immediately dangerous to health and life, but 
will produce marked discomfort, sickness, per-
manent harm, or death after a prolonged expo-
sure or with repeated exposure. Emergency sit-
uations are those that involve actual or potential 
exposure to atmospheres that are immediately 
harmful and dangerous to health or life after 
comparatively short exposures. [Yant 1944] 
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The Occupational Safety and Health Administra-
tion (OSHA) defines an IDLH concentration in 
the hazardous waste operations and emergency re-
sponse regulation as follows: 
An atmospheric concentration of any toxic, cor-
rosive or asphyxiant substance that poses an im-
mediate threat to life or would interfere with an 
individual’s ability to escape from a dangerous 
atmosphere [29 CFR 1910.120]. 
In the OSHA regulation on “permit-required for 
confined spaces,” an IDLH condition is defined 
as follows: 
Any condition that poses an immediate or de-
layed threat to life or that would cause irrevers-
ible adverse health effects or that would interfere 
with an individual’s ability to escape unaided 
from a permit space [29 CFR 1910.146]. Note: 
Some materials (e.g., hydrogen fluoride gas 
and cadmium vapor) may produce immediate 
transient effects that, even if severe, may pass 
without medical attention, but are followed by 
sudden, possibly fatal collapse ~ 6 to 24 hours 
after exposure. The victim “feels normal” from 
recovery from transient effects until collapse. 
Such materials in hazardous quantities are con-
sidered to be “immediately dangerous to life or 
health.” [29 CFR 1910.146] 
In the current respiratory protection standard, 
OSHA states that an IDLH condition is as follows: 
An atmosphere that poses an immediate threat to 
life, would cause irreversible adverse health effects, 
or would impair an individual’s ability to escape 
from a dangerous atmosphere [29 CFR 1910.134]. 
As part of this standard, additional guidance is 
provided by OSHA that dictates the type and appli-
cation of respirators in IDLH conditions. Specific 
information that is provided in the respiratory pro-
tection standard requires:
 • A trained standby person be present with suit-
able rescue equipment when self-contained 
breathing apparatus or hose masks with blow-
ers are used in IDLH atmospheres; and 
 • Persons using air-line respirators in IDLH at-
mospheres must be equipped with safety har-
nesses and safety lines for lifting or removing 
workers from hazardous atmospheres.
The Mine Safety and Health Administration 
(MSHA) defines IDLH as “immediately harmful 
to life” [30 CFR 56/57/5005(c)].  The standard de-
fines “immediately harmful to life” as that used by 
NIOSH to define “immediately dangerous to life or 
health,” which is “acute respiratory exposure that 
poses an immediate threat of loss of life, immedi-
ate or delayed irreversible adverse health effects, or 
acute eye exposure that would prevent escape from 
a hazardous atmosphere.” IDLH values are based 
on a 30-minute exposure duration. 
1.2  The Standards  
Completion Program 
In 1974, NIOSH and OSHA jointly initiated the de-
velopment of occupational health standards consis-
tent with Section 6(b) of the Occupational Safety 
and Health Act of 1970 for substances with then-
existing OSHA permissible exposure limits (PELs). 
This joint effort was called the Standards Comple-
tion Program (SCP) and resulted in the develop-
ment of 387 substance-specific draft standards with 
supporting documentation that contained techni-
cal information and recommendations needed for 
the promulgation of occupational health regula-
tions. Although standards were not promulgated at 
that time, these data became the original basis for 
the NIOSH/OSHA Occupational Health Guidelines 
for Chemical Hazards [NIOSH/OSHA 1981]. 
As part of the respirator selection process for each 
draft technical standard, an IDLH value was deter-
mined for each chemical. The definition used for 
IDLH values that was derived during the SCP was 
based on the definition stipulated in 30 CFR 11.3(t). 
The purpose of deriving an IDLH value was to pro-
vide guidance on respirator selection and to estab-
lish a maximum exposure concentration in which 
workers, in the event of respiratory protection fail-
ure (e.g., contaminant breakthrough in a cartridge 
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respirator or stoppage of air flow in a supplied-air 
respirator), could escape safely when the exposure 
was below the IDLH value. In determining IDLH 
values, the ability of a worker to escape without loss 
of life or irreversible health effects was considered, 
along with severe eye or respiratory tract irritation 
and other deleterious effects (e.g., disorientation or 
incoordination) that could prevent escape. Although 
in most cases, egress from a particular worksite 
could occur in much less than 30 minutes, as a safety 
margin, IDLH values were based on the effects that 
might occur as a consequence of a 30-minute ex-
posure. However, the 30-minute period was NOT 
meant to imply that workers should stay in the work 
environment any longer than necessary following 
the failure of respiratory protection equipment; in 
fact, EVERY EFFORT SHOULD BE MADE TO 
EXIT IMMEDIATELY! 
1.3  Basis of the Original  
IDLH Values 
IDLH values were determined for each substance 
during the SCP on a case-by-case basis, taking 
into account the toxicity data available at the time. 
Whenever possible, IDLH values were determined 
with use of health effects data from studies of hu-
mans exposed for short durations. However, in 
most instances, a lack of human data necessitated 
the use of animal toxicity data. When the findings 
of inhalation studies of animals exposed for short 
durations (i.e., 30 minutes to 4 hours) were the only 
health effects data available, IDLH values were based 
on the lowest exposure causing death or irreversible 
health effects in any species. When lethal dose (LD) 
data from animals were used, IDLH values were es-
timated on the basis of an equivalent exposure to a 
70-kilogram (kg) worker breathing 10 cubic meters 
(m3) of air for an 8-hour period. Because chronic 
exposure data may have little relevance to acute ef-
fects, these types of data were used in determining 
IDLH values only when no acute toxicity data were 
available and only in conjunction with competent 
scientific judgment. In a number of instances when 
no relevant human or animal toxicity data were 
available, IDLH values were based on analogies 
with other substances with similar toxic effects.
The basis for each of the 387 original IDLH val-
ues determined during the SCP was reviewed and 
paraphrased from the individual draft technical 
standards for the publication of the original list of 
IDLH values. Also included is a complete listing of 
references cited in the SCP; in many cases where 
only secondary references were cited, the original 
sources have also been added. Whenever available, 
the references (secondary and primary) were ob-
tained to verify the information cited in the SCP. 
However, a few of the original references, such as 
personal communications and foreign reports, 
could not be located. 
Although 387 substances were originally included 
in the SCP, IDLH values were not determined for 
all of them. The published data at that time for 40 
of these substances—for example, DDT (Chemi-
cal Abstracts Service number [CAS#] 50-29-3) and 
triphenyl phosphate (CAS# 115-86-6)—showed no 
evidence that an acute exposure to high concentra-
tions would impede escape or cause any irrevers-
ible health effects following a 30-minute exposure, 
and the designation “NO EVIDENCE” was used 
in the listing of IDLH values. For all of these sub-
stances, respirators were selected on the basis of 
assigned protection factors. For some (e.g., cop-
per fume (CAS# 7440-50-8) and tetryl (CAS #479-
45-8), an assigned protection factor of 2,000 times 
the PEL was used to determine the concentration 
above which only the “most protective” respira-
tors were permitted. However, for most particu-
late substances for which evidence for establishing 
an IDLH value did not exist (e.g., ferbam [CAS# 
14484-64-1] and oil mist [CAS# 8012-95-1]), the 
use of an assigned protection factor of 2,000 would 
have resulted in the assignment of respirators at 
concentrations that were not likely to be encoun-
tered in the occupational environment. In addition, 
exposure concentrations greater than 500 times the 
PEL for many airborne particulates could result in 
exposures that would hamper vision. Therefore, it 
was decided as part of the SCP (and during the re-
view and revision of the IDLH values) that for such 
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particulate substances, only the “most protective” 
respirators would be permitted for use in concen-
trations exceeding 500 times the PEL. 
IDLH values could not be determined during the 
SCP for 22 substances (e.g., bromoform [CAS# 75-
25-2] and calcium oxide [CAS# 1305-78-8]) because 
of a lack of relevant toxicity data, and therefore, the 
designation “UNKNOWN” was used in the IDLH 
value listing. For most of these substances, the con-
centrations above which only the “most protective” 
respirators were allowed were based on assigned 
protection factors that ranged from 10 to 2,000 
times the PEL, depending on the substance. There 
were also 10 substances (e.g., n-pentane [CAS# 
109-66-0] and ethyl ether [CAS# 60-29-7]) for 
which it was determined only that the IDLH values 
were in excess of the lower explosive limits (LELs). 
Therefore, the LEL was selected as the IDLH value, 
with the designation “LEL” added in the IDLH value 
listing. For these substances, only the “most protec-
tive” respirators were permitted above the LEL in 
the SCP draft technical standards. 
For 14 substances (e.g., beryllium [CAS# 7440-
41-7] and endrin [CAS# 72-20-8]), the IDLH val-
ues determined during the SCP were greater than 
the concentrations permitted on the basis of as-
signed respiratory protection factors. In most in-
stances the IDLH values for these substances were 
set at concentrations 2,000 times the PEL.
1.4  Update of the IDLH  
Values in 1994 
The NIOSH definition for an IDLH condition, 
as given in the NIOSH Respirator Decision Logic 
[NIOSH 2004], is a situation “that poses a threat of 
exposure to airborne contaminants when that ex-
posure is likely to cause death or immediate or de-
layed permanent adverse health effects or prevent 
escape from such an environment.” It is also stated 
that the purpose of establishing an IDLH value 
is to “ensure that the worker can escape from a 
given contaminated environment in the event of 
failure of the respiratory protection equipment.” 
The respirator decision logic uses an IDLH value as 
one of several respirator selection criteria. “Highly 
reliable” respirators (i.e., the most protective respi-
rators) would be selected for emergency situations, 
firefighting, exposure to carcinogens, entry into 
oxygen-deficient atmospheres, entry into atmo-
spheres that contain a substance at a concentration 
greater than 2,000 times the NIOSH recommended 
exposure limit (REL) or OSHA PEL, and entry 
into IDLH conditions. These “highly reliable” res-
pirators include either a self-contained breathing 
apparatus (SCBA) that has a full face piece and is 
operated in a pressure-demand or other positive-
pressure mode or else a supplied-air respirator that 
has a full face piece and is operated in a pressure-
demand or other positive-pressure mode in com-
bination with an auxiliary SCBA operated in a 
pressure-demand or other positive-pressure mode. 
When the IDLH values were developed in the mid-
1970s, only limited toxicological data were available 
for many of the substances. In 1993, NIOSH re-
quested information on the uses of IDLH values in 
the workplace and on the scientific adequacy of the 
criteria and procedures originally used for estab-
lishing them [Federal Register, Volume 58, Num-
ber 229, p. 63379, Wednesday, December 1, 1993]. 
The information received in response to the Federal 
Register announcement was evaluated and used to 
establish future actions concerning IDLH values. 
While new methodology research efforts were 
planned and initiated, NIOSH also decided to re-
view the original IDLH values and revise them as 
appropriate [NIOSH 1994]. The update was com-
pleted in 1994. The 1994 update also included revi-
sions or derivation of IDLH values for 85 substances 
(e.g., benzene [CAS# 71-43-2] and methylene 
chloride [CAS# 75-09-2]) determined by NIOSH 
to meet the OSHA definition of “potential occu-
pational carcinogen,” as given in 29 CFR 1990.103. 
For all of these substances, except ethylene oxide 
(CAS#75-21-8) and crystalline silica (CAS# 14808-
60-7), NIOSH recommends that the “most protec-
tive” respirators be worn by workers exposed at 
concentrations above the NIOSH REL, or at any 
detectable concentration when there is no REL. For 
5NIOSH CIB 66 • Derivation of Immediately Dangerous to Life or Health (IDLH) Values
ethylene oxide and crystalline silica, NIOSH rec-
ommends that the “most protective” respirators be 
worn in concentrations exceeding 5 parts per mil-
lion (ppm) and milligrams per cubic meter of air 
(mg/m3), respectively [NIOSH 1987, 2004].
1.5  Purpose and Objectives  
of the IDLH Values
IDLH values have traditionally been identified as a 
key component of the decision logic for the selec-
tion of respiratory protection devices. For example, 
the NIOSH Respirator Selection Logic [NIOSH 2004] 
states that the purpose of establishing an IDLH value 
is (1) to ensure that the worker can escape from a 
given contaminated environment in the event of 
failure of the respiratory protection equipment and 
(2) to determine a maximum level above which 
only a highly reliable breathing apparatus provid-
ing maximum worker protection is permitted. Ad-
ditionally, IDLH values are based on a 30-minute 
exposure duration. Since the inception of IDLH 
values as part of the SCP, occupational health pro-
fessionals have employed these values beyond their 
initial purpose as a component of the NIOSH Res-
pirator Selection Logic. Examples of such applica-
tions of the IDLH values include the development 
of Risk Management Plans (RMPs) for non-routine 
work practices governing operations in high-risk 
environments (e.g., confined spaces) and the devel-
opment of Emergency Preparedness Plans (EPPs), 
which provide guidance for emergency response 
personnel and workers during unplanned exposure 
events. This CIB presents the methodology used to 
derive IDLH values capable of being used in both 
the traditional role of respirator selection and in 
non-traditional applications, including the devel-
opment of RMPs and EPPs. 
The scientific rationale and derivation process out-
lined in this CIB have been established to ensure 
that a consistent approach is used for development 
of IDLH values. According to this protocol, IDLH 
values are based on health effects considerations 
determined through a critical assessment of the 
toxicology and human health effects data. This 
approach ensures that the IDLH values reflect an 
airborne concentration of a substance that repre-
sents a high-risk situation that may endanger work-
ers’ life or health. The emphasis on health effects 
is consistent with both the traditional use of IDLH 
values as a component of the respirator selection 
logic and the growing applications of IDLH values 
in guiding accident prevention and emergency re-
sponse planning. It is important to note that IDLH 
values are concentrations that may cause adverse 
effects, and thus, they are not intended to be used 
as surrogates for occupational exposure limits 
(OELs). OELs, such as NIOSH RELs, are intended 
to protect workers from adverse health effects as-
sociated with repeated chemical exposure for up to 
10-hour shifts during a 40-hour work week for a 
working lifetime. The IDLH values should not be 
used as comparative indices of toxicity or to infer 
a “safe” level for exposures to chemicals under rou-
tine occupational exposure conditions (see Section 
2.3). A situation resulting in airborne concentra-
tions at or near the IDLH value should be consid-
ered a non-routine event, and exposure duration 
should not exceed 30 minutes. All available precau-
tions should be taken to ensure that workers exit 
the environment immediately if exposures are at or 
near concentrations equivalent to IDLH values.
NIOSH recognizes that in some cases a health-
based IDLH value might not account for all work-
place hazards, such as safety concerns and con-
siderations. Situations and conditions that might 
preclude the use of a health-based IDLH value in-
clude but are not limited to these: 
 • Where the IDLH value based on health effects 
considerations is above the concentration that 
would result in oxygen deprivation (oxygen 
concentration of less than 19.5%). Chemicals 
capable of causing such conditions include 
inert gases such as argon (CAS# 7440–37–1), 
carbon dioxide (CAS# 124-38-9), and nitro-
gen (CAS# 7727-37-9).
 • Where the IDLH value based on health effects 
considerations is higher than a particulate 
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concentration that generates significant haz-
ards from reduced visibility. Such conditions 
may occur in processes that generate dust 
plumes in enclosed areas or confined spaces 
(e.g., grinding, milling, or mining operations) 
and structural fires. 
 • Where the IDLH value based on health-effects 
considerations is greater than 10% of the LEL 
concentration or the minimum concentration 
of gas or vapor in air below which propagation 
of a flame does not occur in the presence of 
an ignition source. Chemicals capable of caus-
ing such conditions include flammable gases 
or vapors such as acetone (CAS# 67-64-1), 
ethyl acetate (CAS# 64-17-5), and n-pentane 
(CAS#109-66-0). 
 • Where the IDLH value based on health ef-
fects considerations is greater than the time-
weighted average (TWA) OEL multiplied by 
the assigned protection factor for the most 
protective respirator. Because IDLH values 
are based on acute exposure and health ef-
fects data, the most protective respirator 
may not be adequately protective for full-
shift exposures at this concentration. Exam-
ples of substances where this situation may 
occur include chromic acid and chromates 
(CAS# 1333–82–0) and lead compounds 
(CAS# 7439–92–1, metal). 
In such cases, it is important that safety hazards 
or other considerations be taken into account. In-
formation on safety hazards will be incorporated 
into the derivation of an IDLH value when appro-
priate. For example, in the event that the derived 
health-based IDLH value exceeds 10% of the LEL 
concentration for a flammable gas or vapor, the 
airborne concentration that is equal to 10% of the 
LEL will become the IDLH value for the chemical. 
The following hazard statement will be included in 
the support documentation: “The health-based 
IDLH value is greater than 10% of the LEL (>10% 
LEL) of the chemical of interest in the air. Safety 
considerations related to the potential hazard of 
explosion must be taken into account.” In addi-
tion, the notation (>10% LEL) will appear be-
side the IDLH value in the NIOSH Pocket Guide 
to Chemical Hazards [NIOSH 2005] and other 
NIOSH publications. Similar statements will be 
developed as needed for other safety hazards and 
considerations. The use of hazard statements and 
notations to provide supplemental information on 
safety hazards and considerations aligns with the 
protocols used to derive the AEGLs by the Na-
tional Advisory Committee for Acute Exposure 
Guideline Levels for Hazardous Substances (NAC/
AEGL Committee) [NAS 2001]. Additional infor-
mation on the establishment of IDLH values based 
on safety hazards can be located in Section 3.6.
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2 Comparison of IDLH Values to Alternative  
 Short-term Exposure Limits/Values 
An important step in the development of IDLH 
values is the review of alternative short-term ex-
posure limits/values developed by other agencies 
and organizations. The review of such information 
serves several purposes: 
 • It is useful for verifying that all key data 
and scientific issues are considered and thus 
serves as one step in verifying that a robust 
literature search has been completed. 
 • It assists in identifying critical issues with 
study design, methodology, or results for 
critical studies that must be considered in de-
veloping an IDLH value. 
 • In some cases, alternative exposure limits/
values may aid in determining a potential 
range for the IDLH value (after taking into 
account the methodology differences used to 
develop various short-term limits/values), as 
described later in this section. 
Because the documentation for the IDLH values 
is intended to be a concise summary document, 
NIOSH incorporates in the IDLH documentation 
information on the acute effects of chemicals and 
selected short-term limits/values from other in-
depth peer-reviewed assessments, for comparison 
purposes. Table 2–1 summarizes several of the 
short-term exposure limits/values most commonly 
evaluated during the derivation of IDLH values. 
There are numerous other sources of short-term 
exposure limits/values, which may be reviewed on 
a case-by-case basis for a particular chemical, de-
pending on availability. 
Although IDLH values may rely on much of the 
same acute health effects information used to de-
rive alternative short-term exposure limits/values, 
there are underlying differences in the intended use 
of the various acute exposure values. Therefore, re-
view of documentation for these alternative short-
term limits/values provides information to guide 
IDLH value development, but the actual proposed 
values are not directly comparable. The remaining 
sections of Chapter 2 discuss the different purposes 
and populations protected by commonly reviewed 
alternative short-term exposure limits/values.
2.1  Acute Exposure  
Guideline Levels 
AEGLs are threshold exposure limits for the gen-
eral public intended to be guideline levels used 
during rare events or single once-in-a-lifetime ex-
posures to airborne concentrations of acutely toxic, 
high-priority chemicals [NAS 2001]. The threshold 
exposure limits are designed to protect the general 
population, including the elderly, children or other 
potentially sensitive groups that are generally not 
considered in the development of workplace ex-
posure recommendations [NAS 2001]. AEGLs are 
based primarily on acute toxicology data and not 
subchronic or chronic data and therefore do not 
reflect the health effects that could result from fre-
quent exposures.
Three levels, referred to as AEGL-1, AEGL-2, and 
AEGL-3, are developed for each of five exposure 
periods (10 minutes, 30 minutes, 1 hour, 4 hours, 
and 8 hours) and are distinguished by varying de-
grees of severity of toxic effects. The three AEGLs 
are defined as follows [NAS 2001]:
 • AEGL-1 is the airborne concentration (ex-
pressed as ppm or mg/m3) of a substance 
above which it is predicted that the general 
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population, including susceptible individu-
als, could experience notable discomfort, irri-
tation, or certain asymptomatic, non-sensory 
effects. However, the effects are not disabling 
and are transient and reversible upon cessa-
tion of exposure.
 • AEGL-2 is the airborne concentration (ex-
pressed as ppm or mg/m3) of a substance 
above which it is predicted that the general 
population, including susceptible individu-
als, could experience irreversible or other 
serious, long-lasting adverse health effects or 
an impaired ability to escape.
 • AEGL-3 is the airborne concentration (ex-
pressed as ppm or mg/m3) of a substance 
above which it is predicted that the general 
population, including susceptible individu-
als, could experience life-threatening health 
effects or death. 
Airborne concentrations below the AEGL-1 repre-
sent exposure levels that could produce mild and 
progressively increasing irritation or asymptomatic, 
non-sensory effects, such as non-disabling odor 
and taste. With increasing airborne concentrations 
above each AEGL, there is a progressive increase 
in the likelihood of occurrence and the severity of 
effects described for each corresponding AEGL. 
Although the AEGL values represent threshold 
levels for the general public, including suscepti-
ble subpopulations, such as infants, children, the 
elderly, persons with asthma, and those with other 
illnesses, it is recognized that individuals, subject 
to unique or idiosyncratic responses, could experi-
ence the effects described at concentrations below 
the corresponding AEGL.
Like the IDLH value, the AEGL-2 is designed to 
protect from irreversible or other serious effects 
and escape-impairing effects. Thus, the effects that 
are the basis for the AEGL-2 closely match those of 
interest for the IDLH value. In addition, the AEGLs 
include a 30-minute value, which is the same dura-
tion of interest for the IDLH values. One significant 
difference between the IDLH value and the AEGL-2 
Table 2–1. Short-term exposure limits/values by other agencies and organizations
Purpose of short-term exposure limit Agency or organization designation
Acute exposure guidelines for protection of the 
general public during emergency or rare releases
Acute Exposure Guidelines Levels (AEGLs)
Emergency Response Planning Guidelines (ERPGs)
Other values as appropriate 
Acute exposure guidelines for potential routine 
acute exposures in the workplace such as short-term 
exposure limits (STELs) 
or Ceiling Limits (“C”).
National Institute for Occupational Safety and Health 
(NIOSH) Recommended Exposure Limits (RELs)
Occupational Safety and Health Administration (OSHA) 
Permissible Exposure Limits (PELs)
American Conference of Governmental Industrial 
Hygienists (ACGIH) Threshold Limit Values (TLVs)®
American Industrial Hygiene Association (AIHA) 
Workplace Environmental Exposure Levels (WEELs)
Other values as appropriate 
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is that the AEGL-2 is designed to protect the gen-
eral population, including potentially sensitive sub-
populations (i.e., children, elderly, and individuals 
with pre-existing health impairments). IDLH values 
are designed for worker populations, which tradi-
tionally exclude the most sensitive subpopulations. 
This assumption is based on the consideration that 
there would be a smaller likelihood for significant 
inclusion of specific sensitive subpopulations in the 
population of working adults. In addition, the se-
lection of the critical effect (health endpoint) and 
interpretation of the severity of the health impact 
to the population of interest (in this case a worker 
population in a high-risk environment) may be dif-
ferent than that used for the AEGL-2. This means 
that given the same set of data, the IDLH value will 
often be in the range of the 30-minute AEGL-2 but 
will vary somewhat because of the fundamental 
differences between the approaches applied to es-
tablish AEGL values and IDLH values for a chemi-
cal. The IDLH value is usually below the 30-minute 
AEGL-3, since, for most chemicals, serious or 
escape-impairing effects relevant for IDLH values 
occur at concentrations below the lethality thresh-
old. In light of these considerations, recent AEGL-2 
and AEGL-3 values can provide a rough gauge for 
identifying a potential range for the IDLH value. 
Exceptions may occur, partially because the AEGL 
process follows fairly strict methodology guidelines 
[NAS 2001], including the use of default approaches 
in the absence of chemical-specific data, whereas 
the process for developing IDLH values relies heav-
ily on the overall weight of evidence, with limited 
use of default procedures. The extensive AEGL 
documentation for each chemical has been thor-
oughly reviewed by expert committees and is often 
a useful resource for de novo analyses. In addition, 
the AEGL documentation includes detailed analy-
sis of all key studies, often including calculation of 
the value of the ten Berge exponent n [ten Berge et 
al. 1986]; for a detailed description of the ten Berge 
exponent, see Section 3.5—Time Scaling. 
The AEGL values are derived by the NAC/AEGL 
Committee, which is a Federal Advisory Commit-
tee Act (FACA) committee established to identify, 
review, and interpret relevant toxicologic and other 
scientific data and to develop AEGLs for high pri-
ority, acutely toxic chemicals (available online at: 
http://www.epa.gov/oppt/aegl/). The NAC/AEGL 
includes members from federal and international 
agencies (e.g., NIOSH, U.S. Environmental Protec-
tion Agency [USEPA], U.S. Department of Trans-
portation [DOT], U.S. Department of Defense 
[DOD], U.S. Department of Energy [DOE], 
Agency for Toxic Substances and Disease Regis-
try [ATSDR], Canadian Government, Netherlands 
National Institute for Public Health and the En-
vironment [RIVM], state agencies and environ-
mental organizations, academia, private industry, 
and international and nonprofit organizations). 
Interim AEGLs prepared by the AEGL Commit-
tee, after stakeholder comment, are reviewed by 
the National Academy of Sciences (NAS)/Nation-
al Research Council (NRC) AEGL Committee be-
fore finalization. 
2.2  Emergency Response  
Planning Guidelines
Emergency Response Planning Guidelines (ERPGs) 
are developed by the American Industrial Hygiene 
Association (AIHA) for emergency planning and 
are intended as health-based guideline concentra-
tions for single exposures to chemicals [AIHA 2006, 
2008]. These guidelines (i.e., the ERPG documents 
and ERPG values) are intended for use as planning 
tools for assessing the adequacy of accident pre-
vention and emergency response plans, including 
transportation emergency planning, and for devel-
oping community emergency response plans. 
As with AEGLs, there are three ERPG guidance con-
centration levels designed for community protec-
tion [AIHA 2006]. However, ERPGs are derived for 
only single-exposure durations of 1 hour. Each of the 
three levels is defined and briefly discussed below:
 • ERPG-1: The maximum airborne concentra-
tion below which it is believed that nearly all 
individuals could be exposed for up to one 
hour without experiencing other than mild, 
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transient adverse health effects or without per-
ceiving a clearly defined objectionable odor.
The ERPG-1 identifies a level that does not 
pose a health risk to the community but that 
may be noticeable because of slight odor or 
mild irritation. In the event that a small, non-
threatening release has occurred, the commu-
nity could be notified that they may notice an 
odor or slight irritation but that concentrations 
are below those which could cause unac-
ceptable health effects. For some materials, 
because of their properties, there may not be 
an ERPG-1. Such cases would include sub-
stances for which sensory perception levels 
are higher than the ERPG-2 level. In those 
cases, the ERPG-1 level would be given as 
“Not Appropriate.” It is also possible that no 
valid sensory perception data are available for 
the chemical. In these cases, the ERPG-1 level 
would be given as “Insufficient Data.”
 • ERPG-2: The maximum airborne concentra-
tion below which it is believed that nearly all 
individuals could be exposed for up to one 
hour without experiencing or developing ir-
reversible or other serious health effects or 
symptoms that could impair an individual’s 
ability to take protective action.
Above ERPG-2, there may be significant ad-
verse health effects, signs, or symptoms for 
some members of the community that could 
impair their ability to take protective action. 
These effects might include severe eye or re-
spiratory irritation, muscular weakness, cen-
tral nervous system (CNS) impairments, or 
serious adverse health effects.
 • ERPG-3: The maximum airborne concentra-
tion below which it is believed that nearly all 
individuals could be exposed for up to one 
hour without experiencing or developing life-
threatening health effects.
The ERPG-3 level is a worst-case planning 
level, above which there is the possibility 
that some members of the community may 
develop life-threatening health effects. This 
guidance level could be used to determine 
the airborne concentration of a chemical that 
could pose life-threatening consequences 
should an accident occur. This concentration 
could be used in planning stages to project 
possible levels in the community. Once the 
distance from the release to the ERPG-3 level 
is known, the steps to mitigate the potential 
for such a release can be established.
Like the IDLH value, the ERPG-2 is designed to 
protect from irreversible or other serious and 
escape-impairing effects and therefore is based on 
effects similar to those considered as the basis for 
IDLH values. Like the IDLH values, ERPGs are 
for acute exposure, but they are based on a 1-hour 
rather than 30-minute exposure. All other things 
being equal, this would mean that ERPG-2 values 
will generally be lower than the corresponding 
IDLH values, since the potential exposure time for 
the ERPG is higher. Moreover, even though ERPGs 
are developed by an occupational health organiza-
tion, ERPGs are more like the AEGLs in that they 
are designed to protect the general population, and 
thus susceptible populations are more of a consid-
eration for ERPGs than for IDLH values.
2.3  Occupational  
Exposure Limits 
OELs are derived by various governmental, nongov-
ernmental, and private organizations for application 
to repeated or daily worker exposure situations. For 
example, in the United States, OELs are developed 
by several organizations. Examples of such orga-
nizations and their respective OEL values include; 
NIOSH RELs, OSHA PELs, MSHA PELs, ACGIH 
TLVs®, and AIHA WEELs®. Although the exact def-
inition varies among organizations (see Glossary), 
the general intent of OELs is to identify airborne 
concentrations of substances in the air to which all 
or nearly all workers can be exposed on a repeated 
basis for a working lifetime without adverse health 
effects. OELs are developed on the basis of available 
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human data (such as results from epidemiologic 
studies or controlled human exposure studies), 
animal toxicologic data, or a combination of hu-
man and animal data. The health basis on which 
exposure limits are established may differ from sub-
stance to substance; protection against impairment 
of health may be a guiding factor for some, whereas 
reasonable freedom from irritation, narcosis, nui-
sance, or other forms of stress may form the basis 
for others. For most OELs, health impairment refers 
to effects that shorten life expectancy, compromise 
physiological function, impair the capability of re-
sisting other toxic substances or disease processes, 
or impair reproductive function or developmental 
processes. Alternative considerations, such as tech-
nological feasibility, analytical achievability and 
economic impact, are often included during the 
establishment of an OEL based on the mandate of 
the organization deriving the exposure limit. For 
this reason, it is important to review the support 
documentation for any OEL to determine its basis 
(i.e., health endpoint versus alternative endpoint) 
and intended purpose.
OELs are guidelines (or regulatory standards, if 
mandated by OSHA and MSHA) intended for use 
in the practice of industrial hygiene, for the con-
trol of potential workplace hazards. OELs are not 
intended for use in other situations, such as the 
evaluation or control of ambient air pollution, or 
for estimating the toxic potential of continuous un-
interrupted exposures or other exposure scenarios 
involving extended work periods, or as proof of ex-
isting disease or physical conditions. OELs neither 
clearly delineate between safe and dangerous con-
centrations nor serve as a relative index of toxicity. 
There are three primary categories of OELs, each 
with a different exposure duration comparison. 
The first category defines the TWA exposure con-
centration for up to a 10-hour workday (NIOSH 
REL) or a conventional 8 hour workday (OSHA 
PEL, MSHA PEL, ACGIH TLV®, or AIHA WEEL) 
during a 40-hour work week, to which it is believed 
that all workers (for the REL and PEL), nearly all 
workers (for the TLV®), or most workers (WEEL) 
may be repeatedly exposed daily without adverse 
effects. It should be noted that because alternative 
considerations (i.e., technical achievability, eco-
nomic impact and analytical feasibility) are often 
included during the derivation of an OEL they may 
reflect an airborne concentration of a chemical for 
which there is residual risk of experiencing adverse 
health effects for some workers. The second catego-
ry of OEL, called short-term exposure limit (STEL) 
and designated by ST preceding the value for 
NIOSH RELs, is a TWA concentration that should 
not be exceeded during any 15-minute period of a 
workday. ACGIH describes the TLV-STEL as the 
concentration to which it is believed that workers 
can be exposed continuously for a short period of 
time without suffering from irritation, chronic or 
irreversible tissue damage, or narcosis of sufficient 
degree to increase the likelihood of accidental in-
jury, to impair self-rescue, or to materially reduce 
work efficiency [ACGIH 2009]. Exposures above 
the TLV-TWA and up to the TLV-STEL should 
not be longer than 15 minutes and should not occur 
more than four times per day, with a minimum of 60 
minutes between exposures in this range [ACGIH, 
2009]. The last category of OELs, referred to as ceil-
ing OELs and designated by ACGIH with a “C” pre-
ceding the value, are the concentrations that should 
not be exceeded during any part of the working ex-
posure, unless otherwise noted [ACGIH 2009].
Like the IDLH values, OELs are aimed at worker 
populations, and therefore consideration of sus-
ceptible populations is of less significance than for 
general population values. STELs and ceiling OELs 
are acute exposure values, whereas the TWA OELs 
are for repeated, chronic exposure. STELs are for 
a shorter duration (15 minutes), compared with 
30-minute IDLH values, and repeated exposures 
are permitted during the work shift at these air-
borne concentrations. STELs can be based on some 
endpoints similar to those that are of concern for 
IDLH values (e.g., chronic or irreversible tissue 
damage, narcosis that would impair self-rescue). 
For other endpoints, the severity for the basis of 
STELs may be less than that for the IDLH value. 
For example, mild irritation that would not be 
escape-impairing and mild narcosis that affects 
work efficiency but is not escape-impairing could 
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be the bases for a STEL but would be considered 
below the threshold of interest for an IDLH value. 
Thus, depending on the nature of the effect caused 
by the chemical, the IDLH value may or may not be 
comparable to a STEL value for the same substance. 
2.4  Other Acute Exposure  
Limits/Values
A number of other governmental agencies and orga-
nizations also develop, or have developed, acute in-
halation exposure limits/values intended to address 
various applications, exposed populations, and du-
rations. These include acute exposure limits/values 
listed in Table 2–2.
Documentation for acute exposure limits/values 
from these selected organizations is reviewed and 
considered if it is deemed to provide specific in-
sights that impact the development or interpreta-
tion of the IDLH value. For example, acute expo-
sure limits/values from other government agencies 
and organizations might be included in the docu-
mentation for IDLH values if they are more recent 
or have unique data not available in other sources. 
Table 2–2. Other sources of acute inhalation exposure limits/values
Governmental agencies  
and organizations
Acute inhalation exposure 
limits/values Sources
Department of Energy (DOE) Temporary Emergency Exposure 
Limits (TEELs)
Craig et al. [2000]; US DOE [2008]
State agencies (California, Texas, 
Minnesota, New York, New Jersey, etc.)
State Exposure Limits MDH [2010]; TCEQ [2010]; Cal/
EPA [2010]; NJ RTK [2010] 
National Academy of Sciences/National 
Research Council (NAS/NRC)
Emergency and Continuous Exposure 
Guidance Levels (EEGLs)
NAS [1986, 2008]
National Academy of Sciences/National 
Research Council (NAS/NRC)
Short-term Public Emergency 
Guidance Levels (SPEGLs)
NAS [1986]
NAS/NRC Spacecraft Maximum Allowable 
Concentration (SMAC)
NASA [1999]
U.S. Environmental Protection  
Agency (USEPA)
Acute reference concentrations (RfCs) USEPA [2010] 
USEPA’s homeland security  
program (DHS)
Provisional Advisory Levels (PALs) 
for Hazardous Agents
US DHS [2009]; Young et al. [2009]
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3 Criteria for Determining IDLH Values
A weight-of-evidence approach based on scientific 
judgment is used in the IDLH methodology, both 
for evaluating the quality and consistency of the sci-
entific data and in extrapolating from the available 
data to the IDLH value. The weight-of-evidence 
approach refers to the critical examination of all 
the available data from diverse lines of evidence 
and deriving a scientific interpretation based on 
the collective body of data, including its relevance, 
quality, and reported results. This is in contrast to 
a purely hierarchical (or strength-of-evidence) ap-
proach, which would use rigid decision criteria 
for selecting a critical adverse effect concentration 
and applying default uncertainty factors (UFs) to 
derive the IDLH value. The documentation of the 
IDLH value for each chemical is not intended to be 
a comprehensive review of all the available studies; 
instead, it focuses on the key data, decisions points, 
and scientific rationale integrated into the over-
all weight of evidence applied to derive the IDLH 
value for a chemical of interest. An example of the 
documentation for development of an IDLH value 
is provided in Appendix A, which explains the logic 
and rationale behind the derivation of the IDLH 
values for chlorine (CAS# 7782-50-5). 
Because IDLH values are often developed from 
limited data, the process for developing a value 
often applies data from multiple lines of evidence 
rather than a single key high-quality study. Over-
all, the following approach is used for deriving 
IDLH values:
 • Critical review of human and animal toxicity 
data to identify potential relevant studies and 
characterize the various lines of evidence that 
can support the derivation of the IDLH value 
 • Application of duration adjustments to deter-
mine 30-minute-equivalent exposure concen-
trations, as well as other dosimetry adjustments 
as needed 
 • Application of a UF for each potential POD 
or critical adverse-effect concentration iden-
tified from the available studies to account 
for issues associated with interspecies and 
intraspecies differences, the severity of the 
observed effects (including concern about 
cancer or reproductive or developmental tox-
icity), and data quality or data insufficiencies 
 • Developing the final recommendation for the 
IDLH value from the various alternative lines 
of evidence, using a weight-of-evidence ap-
proach, from all of the data.
Figure 3–1 provides a detailed summary of the key 
steps in derivation of IDLH values.
This process (see Figure 3–1) is conceptually simi-
lar to that used in other risk assessment applica-
tions, including these steps:
 • Hazard characterization 
 • Identification of critical effects 
 • Identification of a POD 
 • Application of an appropriate UF based  
   on the study and POD 
 • Determination of the final risk value. 
The use of a weight-of-evidence approach allows 
for the integration of all available data that may 
originate from different lines of evidence into the 
analysis and the subsequent derivation of an IDLH 
value. Ideally, this ensures that the analysis is not 
restricted to a limited dataset or a single study for 
a specific chemical. In particular, application of the 
appropriate UF to each potential POD allows for 
consideration of the impact of the overall dataset 
as well as the uncertainties associated with each 
potential key study in determining the final IDLH 
value. See Appendix A for an example of how a 
typical dataset is evaluated to derive an IDLH value. 
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As illustrated in the remainder of this CIB, deriva-
tion of IDLH values uses a systematic data evalu-
ation process that gives preference for data that 
provide the greatest degree of confidence in the 
assessment. The approach describes some overall 
preferences that define a general data hierarchy, 
but the methodology allows for all of the data to 
be evaluated by means of a weight-of-evidence 
approach to develop a toxicologically meaningful 
IDLH value that is consistent with the dataset as 
a whole. Implementing such a procedure requires 
considerable expertise and relies heavily on weigh-
ing various lines of evidence, with vetting by multi-
ple scientists through a rigorous peer review process. 
Thus, although the following sections describe gen-
eral processes and priorities for use of the data, these 
approaches are provided as general guidance, and 
the focus is on interpretation of the overall database.
3.1  Importance of Mode of  
Action and Weight-of- 
Evidence Approach
The mode of action (MOA), meaning a general de-
scription of how a chemical exerts its toxic effects, 
is an important part of the evaluation of chemical 
data and development of IDLH values. MOA can 
be thought of as a general category of how a chemi-
cal acts to cause adverse effects. Note that the MOA 
is a general description of the biological basis for 
toxicity and does not require the detailed level of 
understanding implied by mechanism of action. 
The MOA for a chemical is identified on the basis 
of the observed toxic effects, any mechanistic data, 
structure-activity data, and information on related 
chemicals; many chemicals act by more than one 
MOA. For example, many solvents cause both re-
spiratory irritation and CNS effects. Some of the 
more common classes of MOA that are encoun-
tered in developing IDLH values, and examples of 
chemicals that fall into these classes, include:
 • Irritants: All chemicals in this group induce 
sensory irritation that is caused by trigeminal 
nerve stimulation and manifests as pain 
within the mucous membranes at the sites of 
contact. Chemicals such as capsaicin (CAS# 
618-92-8) act in this manner without causing 
tissue damage. However, most sensory irri-
tants can cause cytotoxicity (i.e., inflammation 
and tissue damage), with severity increasing in 
proportion to airborne concentrations. These 
types of irritants include highly reactive 
and/or corrosive chemicals, including acids, 
bases, and halogen gases. Endpoints com-
monly reported include eye, nose, and throat 
irritation, with higher concentrations typically 
leading to irritation and tissue damage lower 
in the respiratory tract. Chemicals in this class 
include organic solvents (e.g., vinyl acetate 
[CAS# 108-05-4]), organic acids (e.g., acrylic 
acid [CAS# 79-10-7]), halogens and other re-
active gases (e.g., bromine [CAS# 7726-95-6]), 
and some metal compounds (e.g., titanium 
tetrachloride [CAS# 7550-45-0]).
 • Nervous System Effects: Chemicals can cause 
nervous system effects by different MOAs. 
Many solvents (e.g., chloroform [CAS# 67-66-
3] and 1,1,1-trichloroethane [CAS# 71-55-6]), 
as well as other chemicals, cause CNS depres-
sion. Clinical signs reported in humans may 
include fatigue, weakness, and headaches. 
Endpoints commonly reported in animals or 
humans include sedation and reduced per-
formance in specialized neurological testing. 
Certain classes of pesticides (e.g., organophos-
phates and carbamates) and nerve agents (e.g., 
sarin [CAS# 107-44-8]) inhibit the action of 
the enzyme acetylcholinesterase. Early signs of 
exposures to such agents include miosis (con-
striction of the eye pupil), excessive salivation, 
and muscle twitching. 
 • Metabolic Toxicants: This class of chemicals 
acts by interfering with the cell’s ability to 
generate and store energy and includes, for 
example, cyanides and azides. Initial effects 
of these chemicals are CNS symptoms (some 
similar to those noted previously for CNS 
depressants) and toxicity, ultimately leading 
to respiratory failure. 
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 • Target Organ Toxicants: Certain organs or 
organ systems, such as the liver or kidney, are 
the site of toxicity for many chemicals. Organ-
specific effects are typically not evaluated in 
acute lethality studies. In-depth study of a 
single inhalation exposure may include evalu-
ation of histopathology or clinical chemistry 
for certain organ systems. Also, acute poison-
ing incidents in humans may indicate that the 
liver or kidney is a target. These organ systems 
are frequently the most sensitive systemic tar-
gets because of the high blood flow to these 
organs and their capacity for metabolizing 
chemicals to more reactive forms. 
In addition, some chemicals target specific 
organs or have unique systematic effects. For 
example, arsine (CAS# 7784-42-1) causes 
hemolysis (breakage of red blood cells), with 
accompanying symptoms of headache, nau-
sea, and shortness of breath. A number of 
halogenated hydrocarbons (e.g., vinyl chlo-
ride [CAS# 75-01-4], HFC-134a [CAS# 811-
87-2], and HCFC-141b [CAS# 1717-00-6]) 
cause cardiac sensitization. Chemicals, such 
as hexafluoroacetone (CAS# 684-16-2) and 
1-bromopropane (CAS# 106-94-5), cause 
reproductive toxicity and development ef-
fects. Also, hormonally-mediated effects 
can be suggested by direct observations of 
effects on reproductive function or toxicity 
studies evaluating fetal development.
 • Asphyxiants: Inert gases (e.g., nitrogen 
[CAS# 7727-37-9] and argon [CAS# 7440-
37-1]) cause health effects by displacing oxy-
gen. Chemical asphyxiants (e.g., carbon mon-
oxide [CAS# 630-08-0], hydrogen cyanide 
[HCN; CAS# 74-90-8], and hydrogen sulfide 
[CAS# 7783-06-4]) can interfere with the 
body’s ability to use oxygen. Some early symp-
toms of asphyxiation include headache, rapid 
breathing, heart palpitations, and lethargy.
MOA is considered as part of the evaluation of 
need for and adequacy of UF in extrapolation 
from various points of departure. The MOA of a 
substance is used during the derivation of IDLH 
values to determine UF, time extrapolation, choice 
of POD, and consideration of interspecies differ-
ences. Below are some examples of how MOA af-
fects these considerations. 
 • A smaller UF is used when the endpoint 
is known to be very sensitive (e.g., cardiac 
sensitization in response to an epinephrine 
challenge, which is considered a sensitive 
marker of a severe effect). 
 • MOA information may also be used to sup-
port a flatter time extrapolation curve for 
sensory irritants, based on the observation 
that effects from such chemicals (after the 
first few minutes of exposure) are driven 
primarily by concentration and less by dura-
tion of exposure. 
 • MOA information indicating that the chem-
ical targets the route of entry, with resulting 
effects such as eye, nose, and throat irrita-
tion, would indicate that the route-to-route 
extrapolation is not appropriate. 
 • MOA information may suggest the use of 
surrogates when information on the chemi-
cal of interest is limited or when a breakdown 
product is identified as being the primary 
cause of toxicity.  For example, HCN is com-
monly used as a surrogate for acetocyanohy-
drin (CAS# 78-97-7), which spontaneously 
forms acetone and HCN. Another example 
is the use of hydrogen chloride (CAS# 7647-
01-0) as a surrogate for chlorosilanes, which 
decomposes when exposed to water (i.e., hu-
midity) to form hydrogen chloride and silan-
ols. In both cases, the surrogates (i.e., HCN 
and hydrogen chloride) are directly linked to 
the severity of the toxic effect. 
 • Finally, MOA information may suggest po-
tential refinements to the dose–response 
analysis. For example, carbon monoxide 
toxicity is due to the formation of carboxy-
hemoglobin (COHb), and the IDLH value 
for carbon monoxide is based on calculated 
COHb levels. 
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3.2  Process for Prioritization  
of Chemicals
In addition to serving as a crucial factor in the se-
lection of respiratory protection equipment, IDLH 
values play an important role in planning work 
practices surrounding potential emergency high-
exposure environments in the workplace and in 
guiding actions by emergency response personnel 
during unplanned exposure events. Ideally, such 
guidance values would be available for all chemi-
cals that might be present under high-exposure 
situations. However, the development of IDLH 
values is not necessary for many chemicals, such 
as those with very low exposure potential or those 
that do not exhibit significant acute toxicity via the 
inhalation route. A prioritization process is used 
by NIOSH to ensure that resources allocated to 
IDLH value development yield the greatest im-
pact on risk reduction. This process takes into 
account both toxicity and exposure potential and 
is applied to a broad range of potentially hazardous 
chemicals (e.g., chemical warfare agents, industrial 
chemicals, or agrochemicals) subject to emergency 
or uncontrolled releases. A qualitative algorithm is 
used to generate a priority ranking. This process 
provides initial priority rankings based on a sim-
ple approach that uses readily available sources 
of information. More sophisticated hazard- or 
risk-based ranking schemes could be used, but 
gathering and analyzing the data would require 
the same approximate effort required to actually 
derive an IDLH value. A complex ranking ap-
proach would not meet the primary objective to 
quickly and efficiently identify chemicals of great-
est concern. The resulting priorities are further 
modified according to NIOSH emphasis areas. For 
example, chemicals can be added or removed from 
the priority list on the basis of new information re-
lated to toxicity or exposure potential. The develop-
ment and use of a documented prioritization pro-
cess allows for more frequent updating by NIOSH 
of both input data and prioritization criteria to 
meet changing needs. The prioritization approach 
is described more fully in Appendix B. 
3.3  Literature Search Strategy 
NIOSH performs in-depth literature searches to 
ensure that all relevant data from human and ani-
mal studies with acute exposures to the substance 
are identified. An initial literature search is done, 
including searches for information from the sources 
listed in Table 3–1.
Electronic searches of these databases are conduct-
ed with limitations on search dates. The databases 
are searched for studies pertinent to acute inhala-
tion toxicity, with use of the search terms summa-
rized in Table 3–2. 
The electronic literature searches are screened for 
relevant articles, and a bibliography of relevant 
literature is compiled that identifies studies for 
retrieval and review. Peer-reviewed toxicology re-
views are also examined, including those identi-
fied by searching the databases and organization 
websites, as noted in Table 3–1. Toxicology reviews 
that are routinely used to identify pertinent litera-
ture for developing the IDLH value include those 
published by ACGIH (i.e., TLV® and Biological 
Exposure Indices), AIHA (i.e., ERPG and WEEL 
documentation), ATSDR (i.e., Toxicology Profiles), 
National Toxicology Program (NTP), NIOSH (i.e., 
REL documentation), NRC (i.e., AEGL documenta-
tion), OSHA (i.e., PEL documentation), WHO (i.e., 
Environmental Health Criteria) and USEPA (i.e., 
IRIS Toxicological Reviews). Other key unpub-
lished literature, such as toxicological reports on 
file with the USEPA as part of the Toxic Substance 
Control Act Section 8D, may become available 
from stakeholders and other interested parties dur-
ing the external and stakeholder review process. 
3.4  Determining the Critical  
Study and Endpoint
Development of an IDLH value begins with the 
critical evaluation and array of the available animal 
toxicity and human health effects data. In order to 
effectively evaluate the data, it is useful to array the 
following information: 
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 • Description of the test species 
 • Health endpoints evaluated
 • Exposure concentrations
 • Critical effect levels (e.g., NOAELs, LOAELs, 
LC50 values) 
 • Duration of the exposure for the study. 
Once this information is compiled, critical ef-
fect levels are adjusted to a 30-minute-equivalent 
concentration to derive a POD estimate for each 
Table 3–1. Literature search sources
Database Link
Centers for Disease Control and Prevention (CDC)/









National Library of Medicine (NLM), Haz-Map http://hazmap.nlm.nih.gov/
NLM, Hazardous Substance Data Bank (HSDB) http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB
International Agency for Research on Cancer (IARC) http://www.iarc.fr/
Environmental Protection Agency (EPA) Toxic 
Substance Control Act (TSCA) Section 8(e) Notices
http://www.epa.gov/oppt/tsca8e/index.html
World Health Organization (WHO)/IPCS International 
Chemical Safety Card (ICSC)
http://www.ilo.org/public/english/protection/safework/
cis/products/icsc/dtasht/index.htm
International Toxicity Estimates for Risk (ITER) http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?iter
New Jersey Hazardous Substance Fact Sheets (NJ-HSFS) http://web.doh.state.nj.us/rtkhsfs/indexfs.aspx
NIOSHTIC2 http://www2a.cdc.gov/nioshtic-2/default.asp
NLM, PUBMED http://www.ncbi.nlm.nih.gov/pubmed/
National Institute for Occupational Safety and Health 
(NIOSH)/Registry of Toxic Effects of Chemical 
Substances (RTECS)
http://www.cdc.gov/niosh/rtecs/
NLM, Toxicology Literature Online (TOXLINE) http://toxnet.nlm.nih.gov/cgi-bin/sis/
htmlgen?TOXLINE
Web of Science http://thomsonreuters.com/products_services/
science/science_products/scholarly_research_analysis/
research_discovery/web_of_science
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study or study endpoint. Through the application 
of the weight-of-evidence approach described in 
this document, the critical study that contributes 
most significantly to the qualitative and quantita-
tive assessment of risk is selected as the basis of an 
IDLH value. Appendix A provides an example of 
how such information is compiled and used in the 
derivation of the IDLH value for chlorine (CAS# 
7782-50-5). The weight given to each study in se-
lection of a final POD is based on the reliability 
of the reported findings (as determined from an 
assessment of study quality), the relevance of the 
study type for predicting human effects from acute 
inhalation exposure, and the estimated 30-minute 
adjusted effect level. 
3.4.1  Study Quality Considerations
For toxicology studies, quality considerations that 
affect the reliability of each study include the key 
elements of the study design and the adequacy of 
study documentation. For example, such aspects of 
study quality might include the following:
 • Relevance of the exposure regimen to a single 
30-minute inhalation exposure 
 • Quality of atmosphere generation system 
and analytical techniques used to assess ex-
posure conditions
 • Degree of evaluation of toxic endpoints
 • Number of animals used and relevance of the 
test species to humans. 
Other considerations for evaluation of study qual-
ity include the reliability of the cited data source, 
whether the study adhered to or was equivalent to 
current standards of practice (e.g., USEPA or Or-
ganisation for Economic Co-operation and Devel-
opment [OECD] test guidelines), and whether good 
laboratory practices (GLPs) were followed. These 
considerations are evaluated for each study accord-
ing to the general concepts outlined by Klimish et 
al. [1997]. Although a single authoritative guide 
to such study quality evaluation for epidemiology 
studies is not available, human effects data stud-
ies are judged on the basis of current standards of 
practice for conducting epidemiology or clinical 
studies [USEPA 1994; Federal Focus Inc. 1995; 
Lewandowski and Rhomberg 2005]. Consistency 
of effects across studies and consistency based on 
other information available about the chemical 
(e.g., oral data, structure-activity data) are used to 
assess the quality of individual studies.
Selection of the critical study to serve as the basis 
for the IDLH relies heavily on study quality consid-
erations. A high-quality study might be chosen as 
the basis for the IDLH value, even if a lower IDLH 
value could be generated from a low-quality study, 
where the evaluation of quality casts doubt on the 
reliability of the study results. An LC50 value derived 
from a USEPA or OECD guideline–compliant acute 
lethality study with robust atmosphere generation 
and measurement systems may be selected over a 
lower LC50 value from an older study that used a 
static exposure chamber system and reported only 
nominal air concentrations or that used a small 
number of animals or non-standard test species. 
3.4.2  Study Relevance 
Considerations
The weight-of-evidence approach requires a criti-
cal evaluation of each study as to its relevance to 
the ultimate goal of the IDLH value derivation—
to develop a scientifically-based estimate of the 
30-minute human threshold concentration for se-
vere, irreversible or escape impairing effects. The 
methodology for developing IDLH values follows a 
hierarchical approach based on the following pref-
erence for data: 
 • Acute human inhalation toxicity data 
 • Acute animal inhalation toxicity data 
 • Data for longer-term inhalation studies 
 • Inhalation data for analogous chemicals  
(i.e., toxicological surrogates)
 • Acute animal oral toxicity data.
The IDLH methodology described in this CIB fol-
lows similar principles but is based more on an over-
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all weight-of-evidence approach that considers study 
reliability, quality (as discussed in Section 3.4.1), 
relevance, and the magnitude of the observed effect 
levels. The evaluation of study relevance includes 
the type and severity of the effects observed, study 
duration, and route of exposure.
Other considerations that will be addressed during 
the selection of the key data include the following:
 • Primary versus secondary sources.
 • Peer-reviewed versus non-peer-reviewed studies.
The term primary data refers to information ob-
tained directly from original studies and reports, 
whereas secondary data refers to information sum-
marized within reviews and monographs. Primary 
data are given more weight within the derivation 
of IDLH values, whereas secondary data are used 
to provide background and supporting informa-
tion. An exception to this may occur when critical 
primary data are unobtainable and an IDLH value 
cannot be derived without being based on data 
contained in a secondary source. In such cases, 
the IDLH value may be based on the informa-
tion contained within the secondary data source. 
Some secondary sources provide greater value than 
other sources. For example, authoritative second-
ary sources might include robust toxicity profiles 
that have undergone extensive review, such as the 
ATSDR Toxicological Profiles or EPA IRIS Toxico-
logical Reviews. 
Peer reviewed data are generally preferred as the 
basis of an IDLH value, over data obtained from 
non-peer-reviewed sources. For this reason, peer-
reviewed data take precedent over non-peer-reviewed 
data within the IDLH methodology. Exceptions are 
made when issues with the peer-reviewed data are 
identified or if non-peer-reviewed studies are 
determined to be of higher quality. Non-peer- 
reviewed data may take precedent over peer-reviewed 
data in circumstances such as these:
 • Non-peer-reviewed studies used standard-
ized or guideline-compliant protocols, but 
available peer-reviewed studies used non-
standardized protocols.
 • The toxic effects reported in non-peer-reviewed 
studies align better with the health endpoints 
of interest (e.g., escape-impairing effects, 
irreversible effects, or lethality) than do the 
effects reported in peer-reviewed studies 
(e.g., mild irritation). 
 • Non-peer-reviewed studies demonstrate bet-
ter biological and statistical significance due 
to increased sample size, selection of test spe-
cies, or overall study design, in comparison 
with peer-reviewed studies.
Ultimately, the basis of an IDLH value will result 
from the weight-of-evidence approach incorporated 
into the CIB that reflects the relative strengths and 
weaknesses of all the data. 
3.4.2.1 Relevance of the Type  
and Severity of the Effect
3.4.2.1.1  General considerations in identifying  
the severity of effects for IDLH derivation
Relevance of the effect is evaluated in the context 
of the goal for deriving an IDLH value (i.e., to de-
velop a high-confidence estimate of the 30-minute 
human threshold concentration for severe, irre-
versible, or escape-impairing effects). Studies that 
identify with good precision the actual threshold 
for such effects are rare; therefore, usually it is 
necessary either to extrapolate from an effect level 
that is above a threshold, by relying on a lowest ob-
served adverse effect level (LOAEL) for severe or 
escape-impairing effects, or to use a lower-bound 
estimate of the threshold by relying on a no ob-
served adverse effect level (NOAEL) for severe or 
escape-impairing effects. In some cases, concentra-
tion modeling can be used to further refine such es-
timates on the basis of actual study concentrations. 
All of the data for effects relevant to the IDLH are 
evaluated and used in this effort, including data on 
mortality, severe or irreversible effects, and escape-
impairing effects. Data on exposure levels causing 
less severe effects, which are below the threshold 
of interest, are useful as estimates of the NOAEL 
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for severe effects or escape-impairment. Together, 
these data can describe the exposure–response 
relationship for the chemical of interest, which 
compares the estimated exposure concentration 
to the reported effects. Having an understanding 
of this relationship allows the potential region of 
the threshold concentration to be more accurately 
determined for the most-sensitive severe or escape-
impairing effects. 
Table 3–3 illustrates how the severity of effect is 
taken into account in determining the POD and 
IDLH value. In this case, human data are available 
for a 30-minute exposure that describe the concen-
tration response, from no effects at 10 ppm to mild 
irritation at 20 ppm and severe irritation that was 
considered escape-impairing at 30 ppm. Thus, the 
threshold for an escape-impairing effect in humans 
is between 20 and 30 ppm for a 30-minute exposure, 
and the POD for the IDLH value would be 20 ppm. 
In this case, no concentration–response modeling 
was available to estimate the threshold for severe 
lacrimation and coughing. Application of a typical 
UF of 3 (see Chapter 4) to the NOAEL concentration 
of 20 ppm for mild irritation and coughing would 
generate an IDLH value of 7 ppm, which would be 
lower than appropriate on the basis of the absence of 
any irritant effects at 10 ppm. Thus, in this case, since 
the severity of the effects at 20 ppm was not consid-
ered escape-impairing, the appropriate IDLH value 
would be approximately 20 ppm or less on the basis 
of balancing consideration of the human effect level 
and variability in human sensitivity.
3.4.2.1.2  Consideration of lethality data
Datasets for acute toxicity are often limited to stud-
ies reporting mortality experience in acute animal 
toxicology studies or from case reports describing 
accidental human exposures that include estimates 
of the lethal concentration. Lethality data from 
acute toxicology studies in animals are commonly 
available, and many IDLH values are derived from 
such data. In such cases, information on the thresh-
old for lethality is the preferred basis for an IDLH 
value, rather than an estimate of median lethal con-
centration (i.e., the LC50). Lethality thresholds can 
be estimated from LCLO values (the lowest concen-
tration in the study that caused lethality) if the mor-
tality incidence is relatively low (i.e., 10% or less) or 
can be based on concentration-response models. 
These models can be used to indicate the estimated 
response incidence (percent response) and wheth-
er the estimate is the maximum likelihood estimate 
or a lower confidence limit. For example, a com-
monly reported model value such as an LC01 value 
(the statistically derived air concentration that 
caused lethality in 1% of test animals) is the model 
estimated maximum likelihood concentration as-
sociated with an increased mortality incidence 
of 1% over control values. More recently, studies 
report lethality estimates with use of software that 
provides lower confidence estimates of the con-
centrations. For example, the USEPA provides free 
software for this purpose (available at http://www.
epa.gov/ncea/bmds/). The output from the USEPA 
software is commonly reported as the benchmark 
concentration (BMC) for the maximum likelihood 
Table 3–3. Consideration of severity of effect
Species Endpoint—effect level, ppm Duration, minutes Comments
Human NOAEL—10 30 No irritation
Human NOAEL—20 30 Mild irritation and coughing
Human LOAEL—30 30 Severe lacrimation and coughing
Abbreviations: LOAEL = lowest observed adverse effect level; NOAEL = no observed adverse effect level; ppm = parts per million. 
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estimate or the 95% lower-bound confidence limit 
on the BMC (BMCL). Thus, a BMCL05 is the esti-
mated 95% lower confidence bound on the con-
centration associated with a 5% increased lethality 
response above controls.
Such model-calculated values are preferred over 
LCLO values, because they are not dependent on the 
actual concentrations tested and reflect the response 
at each concentration. Use of a lower confidence 
limit (i.e., the BMCL) also has the advantage of tak-
ing into account the uncertainty in the data and sta-
tistical power of the study. Frequently, the BMCL05 
(i.e., the lower 95% confidence limit on the concen-
tration associated with a 5% response) and BMC01 
(i.e., the central tendency estimate of the concentra-
tion associated with a 1% response) are both calcu-
lated for lethality data, and the lower value is used as 
the lethality threshold. The lower value is often the 
BMCL05, due to the relatively wide confidence limits 
associated with the small sample size. An extensive 
discussion on the application of benchmark dose 
(BMD) within the development of acute emergency 
response guidelines has been included in the AEGL 
SOP [NAS 2001]. This includes key considerations, 
shortcomings, and uncertainty within the process. 
An alternative approach used for estimating a non-
lethal exposure level from LC50 values has been ap-
plied in the AEGL methodology [NAS 2001; Rusch 
et al., 2009]. This approach uses 1/3 of the LC50 value 
as the POD to estimate the boundary between the 
lethality threshold and a non-lethal exposure level. 
When compared to LC01 values and BMCL05 values 
for selected chemicals, in general, 1/3 of the LC50 
value resulted in lower estimates of a non-lethal 
threshold [Rusch et al. 2009]; thus, this is a health-
protective approach. Although the use of lethality 
data as the basis of an IDLH value is not ideal, the 
absence of concentration-response data may require 
the use of LC50 values as a POD. 
Although estimates of a lethality threshold are pre-
ferred over other measures of lethal concentrations, 
in many cases, the only available data from acute 
lethality studies are LC50 values (i.e., concentrations 
associated with a 50% mortality incidence).† If LC50 
value estimates are available for multiple species, 
then the lowest reliable LC50 value in the most rele-
vant animal species is used for extrapolation to pre-
dict human response. If no data are available that 
favor the use of one animal species over another, 
then the most sensitive species is used after consid-
ering study quality. Multiple LC50 values may also 
be available from a single study, including values 
for both sexes individually and for the two sexes 
combined. In such cases, the data are evaluated for 
any clear difference between the sexes. If a clear dif-
ference exists, the LC50 from the more sensitive sex 
is used. If there is no clear difference, the combined 
LC50 value is used, since the combined data provide 
a higher statistical power.
Table 3–4 illustrates different lethality data that 
may be available. In the example cited, three dif-
ferent measures of lethality are available from the 
rat study: the LC50, LCLO, and BMCL05. The selected 
POD for deriving the IDLH value would be the rat 
BMCL05, because this value represents a defined 
response near the threshold for lethality and the 
data show that the rat is more sensitive than the 
mouse. In this case, the BMCL05 resulted in the 
lowest derived value, but the BMCL05 would gener-
ally be preferred, even if it was somewhat higher 
than the LCLO, due to statistical variability related 
to the LCLO and because the BMCL05 reflects the 
variability in the data. The derived IDLH values 
reflect the application of UFs, addressing how far 
the data and endpoints are from the endpoint of in-
terest. Because the goal is to estimate the threshold 
for the severe responses, a larger UF is applied to 
the LC50 value than is applied to measures around 
†LC50 and BMC values are conceptually similar, although 
the BMC approach is a more recent innovation. Both 
values are determined by fitting a flexible mathematical 
curve to the data, and determining the concentration 
corresponding to a specified response. While various 
mathematical models can be fit to the data, the probit 
model is frequently used, as a flexible model that usu-
ally fits acute data well, particularly for lethality data 
(e.g., Fowles et al. [1999]).
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the threshold for lethality, such as the BMCL05 (see 
Chapter 4 for additional discussion of UF).
3.4.2.1.3  Consideration of escape-impairing effects 
For effects other than mortality, reported health ef-
fects in both human and animal studies are classified 
as severe, irreversible, or escape-impairing. Identify-
ing which effects may be escape-impairing is compli-
cated by the fact that observed signs and symptoms 
in animals may differ from those expected to occur 
in humans. For example, the same underlying MOA 
that manifests as changes in respiration rate, nasal dis-
charge, or altered activity level in an acute toxicity test 
in animals may be reported as intolerable irritation in 
humans. For this reason, guidance was developed that 
allows for more consistent assigning of comparative 
severity of observed effects (i.e., severe and irrevers-
ible versus non-severe; escape-impairing versus non-
escape-impairing) for commonly observed adverse 
effects used as the basis of IDLH values. Appendix 
C provides the guidelines for classifying effects com-
monly seen in acute animal studies. 
Generally, basing IDLH values on effects that can 
impair escape relates to consideration of irritation 
responses (e.g., severe eye burning or coughing) 
or impacts on the nervous system (e.g., headache, 
dizziness, drowsiness), although other effects (e.g., 
cardiovascular or gastrointestinal tract effects) may 
also be considered, when warranted. To facilitate 
a consistent approach, qualitative descriptions of 
severity have been developed with study results 
assigned to one of three categories: mild, moder-
ate, or severe. The severity and the type of the ef-
fect are considered in determining whether escape 
impairment is likely. For example, moderate to se-
vere eye irritation, but not mild irritation, is gener-
ally considered an appropriate basis for an IDLH 
value based on escape impairment. For effects on 
the CNS, narcosis or moderate dizziness is consid-
ered sufficiently adverse to impair escape, whereas 
effects such as headache are generally not consid-
ered as an adequate basis for the IDLH value unless 
described in the study as debilitating or occurring 
with other symptoms that directly impaired vision 
or mobility. 
Additional consideration is needed for screen-
ing assays, such as the respiratory depression 50% 
(RD50) assay and cardiac sensitization tests. The 
RD50 assay is a sensitive measure of sensory irrita-
tion, which occurs due to stimulation of trigemi-
nal nerve endings in the cornea and nasal mucosa. 
These effects frequently are due to a decrease in 
respiratory frequency that occurs in some labora-
tory animals when exposed to chemical irritants. 
The RD50 value is considered as part of the overall 







IDLH value  
(ppm) Comments
Rat LC50/1000 30 30 33 Males and females combined
Rat LCLO/400 30 10 40 1/10 died
Rat BMCL05/240 30 10 24 Modeling done by 
the authors
Mouse LC50/2000 30 30 66 Males only
Abbreviations: BMCL05 = lower 95% confidence limit on the concentration associated with a 5% response; IDLH = immediately 
dangerous to life or health; LC50 value = median lethal concentration; ppm = parts per million; UF = uncertainty factor.
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weight of evidence and can be used to support the 
selection of a POD from other studies that iden-
tified the concentration that caused clinical signs 
of irritation or generated histopathologic changes 
consistent with moderate or severe irritant effects 
[Alarie 1981; ASTM 1984; Schaper 1993; Nielsen 
et al. 2007]. The RD50 value can also be used as the 
POD if no reliable LOAEL is available. However, 
the LOAEL is preferred over the RD50 value as a 
POD because of uncertainties in relating the respi-
ratory depression response in rodents to potential 
clinical or tissue changes in humans that would be 
correlated with severe irritation in humans [Bos et 
al. 1992, 2002]. 
Cardiac sensitization is another sensitive endpoint 
[Brock et al. 2003; ECETOC 2009] that serves as the 
basis of some IDLH values. This endpoint reflects a 
serious effect in humans, which is characterized by 
the sensitization of the heart to arrhythmias. Car-
diac sensitization can occur from exposure to some 
hydrocarbons and hydrocarbon derivatives which 
make the mammalian heart abnormally sensitive to 
epinephrine. This can result in ventricular arrhyth-
mias and, in some cases, can lead to sudden death 
[Reinhardt et al. 1971]. The arrhythmia results from 
the hydrocarbon potentiating the effect of endog-
enous epinephrine (adrenalin), rather than a direct 
effect of exposure to the hydrocarbon. As described 
by NAS [2002], “the mechanism of action of car-
diac sensitization is not completely understood but 
appears to involve a disturbance in the normal con-
duction of the electrical impulse through the heart, 
probably by producing a local disturbance in the 
electrical potential across cell membranes.”
Cardiac sensitization is determined by injecting 
the test animal (usually dogs, but rodents are also 
used) with epinephrine to establish a background 
(control) response, followed by an injection of epi-
nephrine during exposure to the chemical of inter-
est. Different doses of epinephrine are often tested 
for the initial injection, and the dose of epinephrine 
chosen is the maximum dose that does not cause 
a serious arrhythmia [NAS 1996]. The test is very 
conservative, because the levels of epinephrine 
administered result in blood concentrations ap-
proximately 10 times the blood concentrations that 
would be achieved endogenously in dogs [Chenge-
lis 1997] or humans [NAS 1996], even under highly 
stressful situations. Thus, even though scenarios 
where IDLH values would apply would be highly 
stressful, the cardiac sensitization test is considered 
a sensitive measure of a severe effect. Cardiac sen-
sitization is relevant to humans, but because of the 
conditions of the assay, which focuses on the mea-
surement of the response to a challenge injection 
with epinephrine, the assay itself is very sensitive 
[Brock et al. 2003; ECETOC 2009]. The sensitivity 
of the assay is considered in the weight-of-evidence 
approach when selecting the POD and in the selec-
tion of the UF.
3.4.2.1.4  Consideration of severe and  
irreversible effects
A variety of health effects may result from acute 
exposures that do not immediately impair escape 
(although over an extended time period these effects 
may be lethal). Severe adverse effects that are not im-
mediately escape-impairing are evaluated on a case-
by-case basis, by weighing considerations such as the 
need for medical treatment, the potential for altered 
function or disability, the potential for long-term 
deficits in function, and the likelihood for secondary 
symptoms that would be escape-impairing. These 
include severe, but reversible, acute effects such as 
hemolysis, chemical asphyxia, delayed pulmonary 
edema, or significant acute organ damage (e.g., 
hepatitis, decreased kidney function). If a chemical 
is suspected of generating such effects, then it is im-
portant to evaluate the design of the study to ensure 
that adequate time was allowed, following comple-
tion of the exposure period, to determine whether 
such latent effects of interest were assessed.
Irreversible target organ effects (e.g., permanent 
functional respiratory impairment or permanent 
neurological impairment) are also considered a 
sufficient basis for an IDLH value. As discussed fur-
ther in the following paragraphs, data on irreversible 
effects of special interest (e.g., reproductive and de-
velopmental toxicity) or effects that have significant 
latency (e.g., cancer) are generally considered as an 
adequate basis for the IDLH value only when single-
exposure studies have been conducted that evaluated 
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these endpoints. For example, if reproductive or de-
velopmental studies involving short-term exposures 
(i.e., 1 day or less) are available and have adequately 
long observation periods to observe delayed effects, 
then they are considered in the development of the 
IDLH value; such studies can be informative regard-
ing the potential for irreversible reproductive or 
developmental effects. These effects are considered 
in the overall weight-of-evidence analysis to ensure 
that the derived IDLH value is sufficiently protective 
against the most sensitive health endpoint, as de-
scribed in the following paragraphs.
Standard developmental toxicity studies are not 
used directly because they typically involve re-
peated exposures (e.g., during all of gestation or 
from implantation through one day prior to ex-
pected parturition), and extrapolation from stud-
ies that involve long exposure periods thereby 
resulting in an unacceptable level of uncertainty. 
However, it is also recognized that some devel-
opmental effects can result from exposure dur-
ing a critical window of development, and that 
the time in which the exposure is administered 
may be more important than exposure duration. 
Therefore, data from developmental studies are 
evaluated in the context of the overall weight-of-
evidence analysis. For example, if developmental 
effects are seen, the data on MOA and the relative 
concentration response for maternal toxicity and 
fetal toxicity are evaluated to determine whether 
an increased UF is needed. Conversely, a potential 
IDLH value derived from systemic toxicity in the 
pregnant female can provide a health-protective, 
lower-bound estimate for the IDLH value, be-
cause the exposure duration of repeated days 
is much longer than the duration of interest—a 
single 30-minute exposure. Use of repeated- 
exposure studies in this manner can provide per-
spective to potential IDLH values derived from very 
high concentration acute studies where a large UF 
leads to relatively low IDLH values that are more 
than adequately protective. Information relating to 
key issues in the use of developmental toxicity data 
during the assessment of the health risks of acute 
exposure scenarios has been published [van Raaij 
et al. 2003; Davis et al. 2009]. These publications 
provide supplemental resources that will be used to 
refine the derivation of IDLH values based on de-
velopmental toxicity data. 
Table 3–5 shows how developmental toxicity data 
can be used to help evaluate an appropriate lower-
bound estimate for the IDLH value. In this case, the 
IDLH value is derived from the 60-minute LC50 
value, as the lowest acute lethality value from the 
studies of relevant duration. (See Section 3.5 and 
Chapter 4.0, respectively, for discussion of the ad-
justment for durations other than 30 minutes and 
UF used to calculate the derived value.) A devel-
opmental toxicity study is also available, in which 
exposure was for 6 hours/day on gestation days 6 to 
20. Because the developmental effect of decreased 
fetal body weight may have resulted from a single 
exposure during a critical window, the exposure 
duration is listed as 6 hours. Because this is a very 
health-protective assumption, the developmental 
toxicity study is not used as the basis for the IDLH 
value, since confidence in the actual acute exposure 
effect level is highly uncertain. However, the derived 
IDLH value does provide a lower-bound estimate, 
since we would not expect the LC50-based IDLH 
value to be lower than the derived value from a 
repeat-exposure study for non-lethal effects. The 
IDLH derived from the LC50 is somewhat higher 
than from the repeated-exposure developmental 
toxicity study; thus, the overall findings are consis-
tent with expectations and the overall dataset pro-
vides reasonable confidence in the selected value. 
Like developmental toxicity studies, reproductive 
toxicity studies tend to involve repeated exposures 
and therefore usually are not used as the basis for 
an IDLH value. However, single-exposure re-
productive toxicity studies that report irrevers-
ible or slowly reversible effects are considered 
in the development of IDLH values. In addition, 
findings of reproductive toxicity coupled with 
MOA data (e.g., data suggesting an effect on hor-
monal control) may suggest the use of an increased 
UF, if the available acute toxicity data are insuffi-
cient to evaluate the concentration–duration re-
sponse for such effects. 
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As noted above, acute animal toxicity studies rarely 
include sufficient post-exposure monitoring to be 
useful for cancer assessment. Even when a study is 
sufficient for evaluating carcinogenicity following 
a single exposure (e.g., Hehir et al. [1981]), such 
as following vinyl chloride exposure, the data are 
usually insufficient for a quantitative calculation of 
cancer risk. Therefore, concern for carcinogenicity 
is addressed by consideration of adding a supple-
mental UF (see Chapter 4). The cancer risk at the 
potential IDLH value can also be estimated and 
compared with a chosen risk level (i.e., a 1 in 1,000 
excess cancer risk) [NAS 2001]. The concentration 
corresponding to a specified risk level is not usu-
ally used as the basis for the IDLH value, because of 
the considerable uncertainty in extrapolating from 
a chronic study to a single exposure. However, if 
the estimated cancer risk at the IDLH value with-
out the supplemental UF is below 1 in 1,000, then 
the supplemental UF is not used. 
3.4.2.2  Relevance of the Exposure 
Duration for Acute Studies
Acute animal inhalation studies reviewed for the 
derivation of the IDLH value may use treatment 
regimens ranging from an exposure duration as 
short as a few minutes (e.g., <10 minutes) to several 
hours (e.g., 8 hours or more). Because the intended 
use of the IDLH value is for the prevention of 
adverse effects that may occur as a result of a single 
exposure for 30 minutes, the derivation of an IDLH 
value is ideally based on:
 • Studies involving exposure for 30 minutes 
 • Studies that have information on the threshold 
for rapidly occurring escape-impairing effects 
 • Studies that include a sufficient observation 
period for potential severe delayed effects. 
Acute studies of durations other than 30 minutes 
that provide information on escape-impairing ef-
fects and severe adverse effects are also desirable 
and used. Although inhalation studies of durations 
other than 30 minutes introduce uncertainties in 
extrapolating effects to a 30-minute duration, they 
are still used after being adjusted to a 30-minute-
equivalent exposure duration, as discussed in detail 
in Section 3.5 on Time Scaling. 
It is recognized that the ideal dataset applied dur-
ing the derivation of an IDLH value will consist of 
high-quality 30-minute inhalation studies with ef-
fects in the severity range of interest. In most cases, 
such datasets are unavailable. Thus, when selecting 
among less-than-optimal study designs to iden-
tify the most appropriate critical study and POD, 
a weight-of-evidence approach is used to select the 
critical study. For example, within a given category 
of studies (e.g., acute lethality studies), preference 











Rat LC50/1800 60 2268 30 75.6 2/4 died—not a 
calculated value
Rat LOAEL/200 360 458 10 45.8 1/21 dams died; fetal 
weight decreased; 
significant reabsorptions 
at 300 ppm; 6 hours/day 
on days 6–20 of gestation
Abbreviations: LC50 = median lethal concentration; LOAEL = lowest observed adverse effect level; ppm = parts per million; 
UF = uncertainty factor.
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is given to high-quality studies of the duration of 
interest (30 minutes) or involving minimal dura-
tion extrapolation (e.g., 20-minute exposure du-
ration is preferred over a 4-hour exposure dura-
tion). However, the relative merits of a well-done 
study of longer duration versus a poorly conducted 
30-minute study must be considered. A well-docu-
mented weight-of-evidence decision is even more 
important when there are no adequate acute inha-
lation studies in humans or animals. In such cases, 
consideration of all other available data is needed, 
including MOA information, repeated-exposure 
studies, studies of exposure routes other than in-
halation (e.g., oral or direct-injection dosing), and 
studies with other (usually structurally related) 
chemicals. MOA understanding is particularly im-
portant in such situations and can determine such 
issues as whether route-to-route extrapolation is 
appropriate, the impact of using data from repeat-
ed-exposure studies, and which structurally related 
chemicals are appropriate to use by analogy. The fol-
lowing examples illustrate the impact of MOA on 
extrapolation decisions.
1. For route-to-route extrapolation: It is inappro-
priate to conduct route-to-route extrapolation for 
irritants, because they target the route of entry. 
2. For duration extrapolation: It may be appropri-
ate to extrapolate from repeated-exposure stud-
ies for irritants, since concentration is often a 
more important determinant of irritation than 
exposure duration. Irritation effects observed 
on the first day of exposure during a repeated-
exposure study may be used as the basis of an 
IDLH value.
Repeated-exposure studies that identify subchronic 
or chronic systemic toxicity (rather than rapid-
onset clinical signs) are not used quantitatively as 
the basis for deriving the IDLH value. However, 
considerations of these other toxicity metrics are 
included in overall database evaluation during the 
consideration of UF and to assess the reliability of 
estimates derived from acute studies. For exam-
ple, if a well-conducted repeated-exposure study 
shows no adverse effect at a given concentration, 
then such a finding can help to determine the lower 
range of potential values for an IDLH value, since 
single acute exposures will usually identify a higher 
POD. In this way, repeated-exposure studies can 
provide a lower bound on the range of potential 
IDLH values for a chemical if the databases of acute 
studies are limited or of marginal quality. 
Table 3–6 illustrates how scientific judgment is 
used in considering duration. In this example, only 
limited acute data are available for the chemical, 
including an RD50 study and one LC50. However, 
some information on the effects of acute exposure 
can be extracted from clinical signs reported for a 
subchronic exposure study in which exposure was 
for 6 hours/day, 5 days/week, for 13 weeks. Clinical 
signs reported at 4.9 ppm were limited to eyes half-
closed during exposure, an indication of eye irri-
tation, but at a level that is not escape-impairing. 
However, at the next higher exposure level (15.3 
ppm), the authors reported burning of the nose 
and eyes, as well as olfactory lesions. Although 
the lesions may have been related to the repeated 
exposure, it is reasonable to assume that the clini-
cal signs of burning eyes and nose were observed 
during the first exposure, and that these effects 
would be escape-impairing. After consideration 
of time adjustments (see Section 3.5) and applica-
tion of the appropriate UF (see Chapter 4.0), the 
LOAEL from the repeated-exposure study was 
used as the basis for the IDLH value, supported 
by the RD50. A slightly higher IDLH value would 
have been calculated from the LC50, but that value 
was not used, since it involves more extrapolation 
due to the severity of the response (lethality). Di-
rect observations from the initial exposure during 
the repeated-exposure study were considered more 
reliable than using the RD50 value directly, based on 
the uncertainties in interpreting the RD50 assay.
3.4.2.3  Relevance of the  
Exposure Measurements
Animal inhalation studies are typically conducted 
using either whole-body or nose-only exposure. 
Both methods have strengths and limitations. 
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Whole-body exposure more closely simulates the 
situation for occupational exposure and includes 
the potential for exposure both via inhalation and 
via dermal exposure to the chemical in the air. 
However, in rodent studies, whole-body exposure 
may also involve ingestion exposure that is not rel-
evant to humans, due to grooming of fur on which 
the chemical has deposited. Nose-only exposure 
avoids the potential for ingestion exposure, but also 
eliminates the potential for human-relevant dermal 
exposure, and may place the animals under addi-
tional stress, because of their being restrained dur-
ing exposure. There is no default preference for one 
exposure scenario over the other. Instead, the stud-
ies and results should be examined to determine 
whether the limitations of either method preclude 
the use of certain studies. For example, the obser-
vation of overt gastrointestinal (GI) effects from 
whole-body exposure suggests the potential for 
confounding by ingestion. In general, both nose-
only and whole-body exposures are considered to-
gether in the overall weight-of-evidence evaluation.
Well-conducted inhalation studies generally report 
both nominal concentrations (the concentration ex-
pected on the basis of the amount of chemical intro-
duced into the exposure system) and the analytical 
concentration (the amount actually measured). The 
two values should be similar; if they are markedly 
different, the reasons and implications for the differ-
ence should be determined. Large differences may 
reflect difficulty in maintaining the exposure atmo-
sphere (e.g., the chemical may be adhering to the 
exposure chamber walls) or other issues, and may 
indicate uncertain study quality. Larger differences 
between nominal and analytical concentrations 
may be seen with static exposure studies (where the 
chemical is introduced into the chamber at the be-
ginning of the experiment), as opposed to dynamic 
studies (where the chemical is continuously cir-
culated and the chemical concentration is actively 
maintained at the target level). Because the analyti-
cal concentration reflects the actual concentration 
to which the animals were exposed, the analytical 
concentration is usually used in IDLH value cal-
culations. However, in some cases, the nominal 
concentration may more appropriately reflect the 
exposure conditions. For example, substances, 
such as trichloromethylsilane (CAS# 75-79-6), sul-
fur trioxide (CAS# 7446-11-9), uranium hexafluo-
ride (CAS# 7783-81-5), and acetone cyanohydrin 
(CAS# 75-86-5), react with the moisture in air to 
produce a variety of hydrolysis products. Table 
3–7 provides examples of hydrolysis products as-
sociated with the previously listed substances. Be-
cause the observed toxicity is due to both the par-
ent chemical and the hydrolysis products, nominal 
concentration is a better indicator of toxicity, since 
it reflects the total burden of toxic constituents, 
whereas analytical concentration would reflect 
only the concentration of the parent compound 
[NAS 2009]. In such cases, the decision of whether 
to use nominal or analytical concentrations de-
pends on the approach that would be used for air 
monitoring and whether it would capture only the 
parent compound or the parent compound and its 
hydrolysis products. 
Care should also be used in considering the 
exposure units. For example, it is appropriate to use 
ppm only for gases and vapors because ppm in air 
refers to molecules of the chemical in air (rather 
than being on a weight basis). The units of mg/m3 
can be used for particulates and aerosols, as well as 
gases and vapors. Although exposures to gases and 
vapors are usually reported in ppm, care is needed 
to ensure that units are not confused. Units of ppm 
can be converted to mg/m3 using the ideal gas law. 
At 1 atmosphere of pressure and room temperature 
(25˚ C), the conversion is as follows:
mg/m3 = ppm × molecular weight/24.45
Difficulties in the determination of exposure concen-
trations may arise because, at high concentrations, 
some vapors may condense into liquid droplets, 
resulting in exposures to a mixture of vapor and 
aerosol. Under such conditions, it is generally rea-
sonable to assume that toxicity is due to the total 
mass of the chemical. However, it should be recog-
nized that vapors and aerosols (e.g., solid particles 
and liquid droplets) are deposited differently in 
the respiratory tract on the basis of many fac-
tors, including the physiochemical properties of 
the chemical [USEPA 1994]. For this reason, the 
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Derived IDLH value 
(ppm) Comments
Mouse RD50/10.4 30 10.4 3 3.5 —
Rat LC50/125 240 250 30 8.3 —
Rat NOAEL/4.9 360 11.2
3
3.7
6 hours/day, 5 days/
week, 13 weeks; eyes 
half-closed during 
exposure
Rat LOAEL/15.3 360 35.0
10
3.5
6 hours/day, 5 days/
week, 13 weeks; 
olfactory lesions, 
burning nose and eyes
Abbreviations: IDLH = immediately dangerous to life or health; LC50 value = median lethal concentration; LOAEL = lowest 
observed adverse effect level; NOAEL = no observed adverse effect level; ppm = parts per million; RD50 value = median 
respiratory depression value; UF = uncertainty factor.
Table 3–7. Examples of hydrolysis products associated with selected chemicals
Chemical names CAS# Hydrolysis products Health effects of hydrolysis products
Trichloromethylsilane 75-79-6 Hydrochloric acid  
(CAS# 7647-01-0) 
Respiratory tract and eye irritation
Sulfur trioxide 7446-11-9 Sulfuric acid  
(CAS# 7664-93-9)
Respiratory tract and eye irritation 
Acetone cyanohydrin 75-86-5 Hydrogen cyanide  
(CAS# 74-90-8);  
Acetone (CAS# 67-64-1) 
Respiratory tract and eye irritation 
Uranium hexafluoride 7783-81-5 Uranyl fluoride  
(CAS# 13536-84-010);  
Hydrogen fluoride  
(CAS# 7664-39-3)
Respiratory tract and eye irritation 
Abbreviation: CAS # = chemical abstract service number
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toxicity related to vapor exposure and aerosol ex-
posure to the same concentration (e.g., mg/m3) of a 
substance may be somewhat different if respiratory 
tract effects are of concern. 
IDLH values derived for aerosols will reflect the 
relevant size fraction. Specific recommendations 
relating to size fractions for aerosols are included 
in the chemical-specific IDLH support documen-
tation when sufficient data are available. The most 
appropriate size fraction is driven by the nature of 
acute toxicity observed. If such data are not avail-
able, the chemical-specific IDLH support docu-
mentation for the aerosol will note that the size 
fraction that represents the greatest hazard could 
not be determined. In such cases, total inhalable 
particulate is used as the basis for the IDLH value. 
3.4.2.4  Other Issues of Study  
Relevance—Use of Surrogates  
and Route Extrapolation
When neither human nor animal acute inhalation 
data are sufficient to derive an IDLH value for a 
chemical of interest, other approaches are consid-
ered, depending on the understanding of the MOA 
and availability of data. Available information on 
surrogates, or related compounds, primary metab-
olites, or key breakdown products (e.g., secondary 
chemical products formed from hydrolysis due to 
moisture in the air) that are closely related to the 
chemical of interest can be used when inadequate 
information is available for the chemical of inter-
est. As an example of the use of a related compound 
during the derivation of an IDLH value, bromine 
pentafluoride (CAS# 7789-30-2) and chlorine 
pentafluoride (CAS# 13637-63-3) differ only in 
the primary halogen atom. Because of their simi-
larities, bromine pentafluoride can be used as a sur-
rogate for chlorine pentafluoride, and the limited 
toxicity data available for bromine pentafluoride 
indicate that its toxicity is comparable to or slightly 
less than that of the chlorine compound. Another 
example is the assessment of the acute inhalation 
hazard of an entire chemical class on the basis of the 
data for a single compound; the NAS/NRC drafted 
AEGL values for multiple chlorosilanes and metal 
phosphides with use of this approach [NAS 2007, 
2009]. This approach takes advantage of knowledge 
about the MOA and the actual form of the toxic-
ity of related chemicals to use the entirety of the 
data for the class of chemicals to develop exposure 
values. For example, for the chlorosilanes the pri-
mary cause of the acute effect of interest (irritation) 
is hydrolysis in moist air to form hydrochloric acid. 
Thus, for the series of related chlorosilanes, the 
IDLH value can be derived from actual testing data 
for the most data-rich member of the family and 
by adjusting the IDLH value for other members ac-
cording to the respective amounts of chlorine at-
oms produced during hydrolysis. A refinement of 
the use of surrogate chemicals or information on 
classes of related chemicals is to use data on the 
relative potency, when adequate data are available 
to quantitatively compare the chemical of interest 
with the surrogate but data for the chemical itself 
are not sufficient to develop an IDLH value. In such 
cases, the toxicity threshold is much better under-
stood for the surrogate than for the chemical of in-
terest, but the threshold for the chemical of interest 
can be adjusted on the basis of relative potency. 
When a surrogate or relative-potency approach 
is used, it is necessary to consider the uncertain-
ties associated with using a limited database for 
the chemical of interest versus the uncertainties 
associated with extrapolation from a surrogate 
chemical. An example of extrapolation from a 
breakdown product is the chemical reaction that 
causes acetone cyanohydrin to form HCN and ac-
etone. The acute toxicity of acetone cyanohydrin is 
driven by exposure to an equimolar (i.e., having an 
equal number of moles) equivalent to HCN. Thus, 
the acute toxicity data for HCN can serve as a sur-
rogate and basis of an IDLH value for acetone cya-
nohydrin [NAS 2002, 2005]. Use of such surrogates 
is not necessary when adequate information on the 
primary chemical is available. In addition, if a sur-
rogate is being considered as the basis for the IDLH 
value, it is important to consider whether other 
aspects of toxicity are associated with the parent 
chemical and whether these aspects are adequately 
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addressed by the surrogate. For example, acetone 
cyanohydrin causes irritant effects that are not seen 
with exposure to HCN, but the most potent escape-
impairing effects are secondary to cyanide action as 
a metabolic toxicant. This results in HCN being the 
most valid surrogate for acetone cyanohydrin.
If no adequate inhalation data are available for the 
chemical of interest or for a potential surrogate, an 
IDLH value may be derived by extrapolation from 
studies that used exposure routes other than inha-
lation, such as oral or intraperitoneal (i.p.) dosing 
studies. As noted above, this route-to-route ex-
trapolation is appropriate only if the effect of in-
terest is systemic (i.e., involves absorption into the 
systemic blood circulation for distribution to an 
internal target tissue). Route extrapolation (e.g., 
from oral or i.p. dosing studies) is not appropriate 
if the chemical’s primary relevant effects for IDLH 
development are as an irritant, or if it is expected 
to target the route of entry (i.e., respiratory tract) 
as the most sensitive end point. The ideal approach 
is to use a physiologically based pharmacokinetic 
(PBPK) model to conduct the route-to-route ex-
trapolation, but it is rare that such data would exist 
(particularly for a chemical for which the inhala-
tion data are insufficient to directly derive an IDLH 
value). In the absence of such a PBPK model, the 
approach is to estimate the concentration to which 
a 70-kg worker could be exposed in order to receive 
the equivalent systemic dose to that delivered in the 
oral or i.p. study. The 30-minute concentration is 
estimated by multiplying the animal dose data by 
the worker body weight (to reach a systemic dose), 
and dividing by the volume of air inhaled per work 
day, as shown in this equation:
Systemic dose equivalent [mg/10 m3] = 
oral or i.p. dose [mg/kg] × 70 kg 
 1.5 m3
This conversion is a health-protective estimate of 
the air concentration that would result in the sys-
temic dose, since a worker breathing at a rate of 
50 liters per minute (L/min) for 30 minutes would 
inhale 1.5 m3 of air. The basis for this decision is 
discussed in greater detail in Appendix E. 
A second consideration in applying route-to-route 
extrapolation is the impact of first-pass metabo-
lism. First-pass metabolism, also known as pre-
systemic metabolism, refers to the metabolism of a 
chemical delivered from the GI tract directly to the 
liver via hepatic blood flow, before distribution to 
the general systemic circulation. First-pass metab-
olism by the liver generally decreases systemic expo-
sure to the parent chemical following oral exposure 
when compared with inhalation exposure. More 
precisely, first-pass metabolism via the respiratory 
tract tends to be of smaller magnitude than for the 
liver resulting in increased systemic exposure to the 
parent chemical and decreased exposure to alter-
native organ systems to metabolites formed in the 
lungs. Quantitatively addressing the implications of 
first-pass metabolism is often difficult, and use of 
a surrogate for which inhalation data are available 
is considered to provide greater weight of evidence 
for chemicals where first-pass metabolism plays an 
important role. Comparing IDLH values derived 
from different approaches (e.g., using a surrogate 
versus using route-to-route extrapolation) can 
provide information on possible uncertainties in-
volved and may help to set the range of reasonable 
IDLH values. Finally, since this approach is based 
on systemic dose, it assumes equal absorption via 
both routes (unless a separate correction is made) 
and ignores issues related to the physical charac-
teristics of the chemical (e.g., gas/vapors versus 
particulate) and implications of particle size and 
dosimetry (i.e., determination of respiratory tract 
region deposition fractions). Where quantitative 
adjustments for differing routes of exposure are 
uncertain, this issue is further considered in the 
selection of additional UFs. Additional consider-
ations for conducting route-to-route extrapolations 
are described in several guidance documents (e.g., 
[USEPA 1994; NAS 2001]).
3.5  Time Scaling
A critical consideration in developing IDLH val-
ues is accounting for exposure duration and the 
extrapolation from the experimental exposure du-
ration to the duration of interest (i.e., 30 minutes). 
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The methods used for these extrapolations in the 
development of IDLH values are similar in many 
ways to the Standing Operating Procedures (SOPs) 
outlined by the NAS for the development of AEGLs 
[NAS 2001]. Issues to be considered include evalua-
tion of the chemical’s MOA and how that is reflected 
in key drivers of toxicity (concentration vs. time); 
modifications to Haber’s rule; and methods for cal-
culating n in the ten Berge modification to Haber’s 
rule. These issues are discussed briefly in the follow-
ing paragraphs and in more detail in NAS [2001]. 
The toxicity of airborne chemicals depends on both 
exposure concentration and exposure duration, as 
well as physiochemical properties that affect respi-
ratory deposition and systemic absorption. Ideally, 
information from validated PBPK or biologically 
based dose–response (BBDR) models is used for 
time extrapolation, but such information is rarely 
available. In the absence of such models, simpler 
concentration–time relationships are used. Histori-
cally, particularly for extended exposure durations, 
toxicity was described as the simple product of con-
centration (Conc) and time, so that Conc × time = k, 
a constant. In other words, if Conc1 × time1 = Conc2 
× time2, then the toxicity would be the same. This 
relationship is described as Haber’s law, or Haber’s 
rule [Haber 1924]. 
The key assumption embedded in the relationship 
of Haber’s rule is that damage (or depletion of pro-
tective tissue response) is irreversible and, there-
fore, that toxicity is cumulative, related to the total 
dose of the chemical [NAS 2001]. This assumption 
is generally not true for single acute exposures 
[NAS 2001]. For example, toxicity due to asphyxi-
ants (e.g., argon or nitrogen) is related to the peak 
concentration of the chemical, rather than the cu-
mulative dose. Sensory irritation and transient acute 
CNS effects may also be influenced more by the ex-
posure concentration than the exposure duration.
Further investigation into the relationship between 
concentration, duration, and toxicity was con-
ducted by ten Berge et al. [1986], who proposed 
the following relationship between Conc and du-
ration (time, t): Concn × t = k. These investigators 
examined the data on 20 irritant and systemically 
acting gases and vapors; the results of this inves-
tigation indicated that n was ≤3 for lethality data 
from 18 of the 20 chemicals. This study is one of the 
primary published sources for values of n. Further-
more, based on the finding in this study that an n 
of 3 covers 90% of the chemicals in the dataset, the 
default value of an n for extrapolating from longer 
durations to shorter durations was chosen to be 3, 
as a health-protective approach.
The following approach is used in extrapolating 
across durations within the IDLH methodology:
1. No extrapolation is needed if the study of inter-
est involved exposure for 30 minutes; the em-
pirical data are used directly.
2. If information on the value of n is available from 
the original paper of ten Berge et al. [1986] or 
from authoritative reviews (e.g., AEGL docu-
ments), then that value is used. Note, however, 
there are caveats to the use of the ten Berge data, 
and other considerations in the choice of n. In 
general, a published value of n will be used di-
rectly only for studies reporting the same effect 
or effects related to the same underlying toxic 
mode of action. Use of the published values of n 
for application to studies conducted in different 
species or for different effects is done on a case-
by-case basis, with rationale provided. 
3. If no value of n is available in the literature, n 
can be mathematically derived directly from the 
key studies of interest and applied with the same 
caveats as noted in item 2.
4. If the data are not available to support the deri-
vation of n, then a default of 1 is used if the 
duration of the study of interest is less than 30 
minutes, in which case the ten Berge equation 
defaults to Haber’s rule. Conversely, if the du-
ration of the study of interest is more than 30 
minutes, then the default of 3 is used for n. This 
approach generally yields health-protective es-
timates for the 30-minute equivalent POD, as 
shown in Appendix E–2.
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5. In limited cases, the overall dose–response data 
and the mode of action information may suggest 
that the observed acute effects are independent 
(or nearly independent) of exposure duration, 
and that exposure concentration can be used 
with no further duration adjustment. If the POD 
is used from studies of durations other than 30 
minutes without adjusting to a 30-minute equiv-
alent value via the ten Berge correction, the ra-
tionale for this decision will be described in the 
documentation of the IDLH value. 
Additional information and illustration on the ap-
plication of time scaling within the IDLH method-
ology are included in Appendix E–2.
3.6 Inclusion of Safety 
Considerations 
Safety hazards are considered during the derivation 
of IDLH values to ensure the protection of worker 
safety and health. One particular consideration in 
the derivation of IDLH values is the potential for 
explosive concentrations of a flammable gas or va-
por to be achieved at toxicologically relevant air 
concentrations. Maintaining safety considerations 
in the process for this methodology update is con-
sistent with the prior method used to develop IDLH 
values. For gases and vapors, NIOSH has adopted 
a threshold of 10% of the LEL as a default basis for 
the IDLH values based on explosivity concerns. 
This threshold aligns with the airborne concentra-
tions of a flammable gas, vapor or mist identified 
by OSHA as a hazardous explosive condition [29 
CFR 1910.146(b)]. In such events, when the air 
concentration that corresponds with 10% of the 
LEL is less than the health-based value using the 
approach outlined in Chapter 3, this air concentra-
tion will become the default IDLH value. The fol-
lowing hazard statement will be included in the 
support documentation: “The health-based IDLH 
value is greater than 10% of the LEL (>10% LEL) 
of the chemical of interest in the air. Safety consid-
erations related to the potential hazard of explo-
sion must be taken into account.” In addition, the 
notation (>10% LEL) will appear beside the IDLH 
value within the NIOSH Pocket Guide to Chemical 
Hazards [NIOSH 2005] and other NIOSH publica-
tions. 
For dust, the equivalent default approach would be 
using 10% of the minimum explosive concentra-
tion (MEC). However, determining the combusti-
bility of dusts is too complex to assign a single de-
fault measure. Dust combustibility and explosivity 
are dictated by the relationships among substance 
and scenario-specific factors including (1) particle 
size distribution, (2) minimum ignition energy, (3) 
moisture content, (4) explosion intensity and (5) 
dispersal in air [Cashdollar 2000]. The ability to 
quantify combustible dust specific concentrations 
for application of an IDLH is often not possible 
given the absence of critical chemical-specific data, 
such as the MEC or the other previously identified 
factors. NIOSH will critically assess the explosive 
nature of a dust when sufficient technical data are 
available.  If determined to be appropriate, the find-
ings of this assessment will be incorporated in the 
derivation process to ensure that the IDLH value 
protects against both health and safety hazards. 
When a dust has been identified as combustible, 
NIOSH will include the following hazard state-
ment: “Dust may represent an explosive hazard. 
Safety considerations related to hazard of explo-
sion must be taken into account.”   In addition, the 
notation (Combustible Dust) will appear beside the 
IDLH value in the NIOSH Pocket Guide to Chemi-
cal Hazards [NIOSH 2005] and in other NIOSH 
publications. Supplemental information on the 
combustibility of dust can be located on the OSHA 
Combustible Dust webpage (http://www.osha.gov/
dsg/combustibledust/). 
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4 Use of Uncertainty Factors 
4.1  Application of  
Uncertainty Factors
As noted in prior sections of this CIB, the first step 
in the development of an IDLH value is to deter-
mine POD estimates adjusted to a 30-minute-
equivalent exposure. However, in many cases the 
available POD values need to be further adjusted to 
develop an IDLH value that protects workers from 
potential lethal, severe or irreversible, or escape-
impairing health effects. Thus the IDLH value can 
be represented as:
IDLH Value =
 POD (e.g., 30-min-equivalent LC50 
 value, LCLOvalue, LOAEL, or NOAEL) 
Total UF
The application of UFs is needed to account for 
uncertainties related to extrapolation from the 
concentration that caused effects in the selected 
toxicity study to those that would be expected to 
be below the threshold for such effects in workers 
exposed for up to 30 minutes. For example, if the 
most appropriate POD was an LC50 value in rats 
from a 30-minute exposure study, then use of this 
value directly as the IDLH value would clearly not 
be acceptable since a sub-threshold concentration 
for humans is needed. Dividing the selected POD, 
such as the LC50 value in this example, by an ad-
ditional UF would then reduce the IDLH value to a 
lower concentration well below the LC50 value. 
In general, the UFs need to address all key areas of 
uncertainty that result from extrapolating from the 
available studies. Most organizations that develop 
exposure values/limits consider the following key 
areas of uncertainty:
 • Interspecies variability in sensitivity: This 
area addresses differences in sensitivity between 
the test species (e.g., mouse, rat, etc.) and the av-
erage human for the population of interest (i.e., 
in the context of IDLH application, workers). 
 • Human variability in sensitivity: This area 
addresses differences in sensitivity between 
the average human from the population of 
interest to the sensitive component of the 
population of interest. 
 • Severity of effect: Because the IDLH value 
is intended to be below a concentration that 
will cause death or severe, irreversible, or 
escape-impairing effects, the UF needs to 
account for extrapolation from a POD that 
caused such responses in the selected toxi-
cology study to a concentration below the 
threshold for these effects. 
 • Duration of exposure: Some organizations 
that develop exposure values/limits include 
consideration of the duration of the study 
that served as the POD in the UF determina-
tion and its relevance to the duration of in-
terest. In the context of IDLH development, 
this area of uncertainty is addressed through 
duration adjustments of the POD rather than 
the explicit application of a UF. 
 • Other database deficiencies: When da-
tasets available to develop IDLH values are 
very limited, it is necessary to account for the 
possibility that the available studies did not 
identify the most sensitive endpoint relevant 
to IDLH development. In such cases it is ap-
propriate to increase the UF to account for 
this uncertainty. 
An approach used by many organizations, such as 
by USEPA for developing reference concentrations 
[USEPA 1994] and for the AEGL process [NAS 
2001], involves consideration of these separate 
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areas of uncertainty and the multiplication of UFs for 
each of these areas to derive the final cumulative UF. 
The IDLH methodology is a modification of this 
approach that blends the rigor of full consideration 
of the relevant areas of uncertainty embedded in 
the USEPA and AEGL approaches with the flex-
ibility to fully use the limited data from multiple 
lines of evidence often encountered in IDLH devel-
opment. Overall, the assignment of UFs for IDLH 
derivation includes two steps: 
1. Selection of an appropriate preliminary UF range
2. Modification of this preliminary range to select 
a final value. 
The preliminary UF ranges are based on consider-
ation of the study design and the adverse health effect 
occurring at the POD. Use of a preliminary range of 
values helps to ensure consistency in application of 
UFs within the IDLH development effort for diverse 
chemicals. However, modification of the UF is often 
required on the basis of unique issues arising from 
the review of the database for each unique chemical. 
Thus, the IDLH methodology captures the need to 
use a consistent approach for UF application while 
maximizing the ability to make informed decisions 
based on weight-of-evidence considerations.
4.2  The NIOSH IDLH 
Value Uncertainty 
Factor Approach
As discussed regarding the overall UF approach, 
the analysis focuses on the weight-of-evidence ap-
proach using all the relevant data. Thus, a range of 
preliminary UFs is shown for each of the typical 
types of effect levels that are available as a POD. 
However, the final UF applied is determined from 
the weight-of-evidence evaluation for each chemi-
cal that allows for modifying the preliminary UF on 
the basis of additional considerations unique to the 
dataset. The preliminary UF ranges are shown in 
Table 4–1. The most common UFs for a given data 
type are shown, but the range indicates how this 
value is commonly adjusted up or down according 
to the entirety of the database, as described further 
in this section. The preliminary UFs are applied as 
multiples of 1 or 10, with use of an intermediate 
value of 3. The value of 3 represents one half of the 
log10 unit (3.16 rounded to 3) as the minimum in-
crements that are used for the UF adjustments to 
reflect the level of precision for such an approach. 
Although the value of 3 is used in place of 3.16 
during the discussion of UFs, caution should be 
applied when multiplying UFs of 3 together. For 
Table 4–1. Typical UF ranges
Point of departure Typical UF range*
LC50 (in an animal study) 10 to 100
LC01, LCLo, or BMCL10 for lethality in animals 3 to 30
LCLo in humans 1 to 10
LOAEL for an escape-impairing or irreversible effect in animals 3 to 30
NOAEL for an escape-impairing or irreversible effect in animals, or animal RD50 1 to 10
LOAEL for an escape-impairing or irreversible effect in humans 1 to 10
NOAEL for an escape-impairing or irreversible effect in humans 1 to 3
Abbreviations: BMCL10 = lower confidence limit on the concentration associated with a 10% response; IDLH = immediately 
dangerous to life or health;  LC01  = the statistically derived air concentration that caused lethality in 1% of test animals;  LC50 
= median lethal concentration; LCLO = lowest concentration of a substance in the air reported to cause death;  LOAEL = lowest 
observed adverse effect level; NOAEL = no observed adverse effect level; UF = uncertainty factor.
*Typical UF Range is based on the information presented in Appendix D.
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example, when multiplying two UFs of 3 together 
(e.g., 3 × 3), the product will be 10, not 9. This is 
also illustrated by the multiplication of three UFs of 
3, that is, 3 × 3 × 3 will equal 30, not 27. 
Selection of values other than the preliminary UF 
for deriving an IDLH value is common, reflecting 
the use of a weight-of-evidence approach and the 
sometimes-conflicting data from multiple lines of 
evidence. Common situations that lead to move-
ment away from the preliminary UF value relate to 
evaluation of data for the areas of uncertainty and 
extrapolation noted in the prior section. 
 • Interspecies variability in sensitivity: If 
chemical-specific data are available to help 
determine the magnitude of the differences in 
species sensitivity, then such data are used to 
refine the size of the final UF. For example, if 
information about specific sensitivity due to 
differences in species metabolism is available, 
the UF applied to the POD from an animal 
study is adjusted accordingly (either up or 
down, depending on the data). If health ef-
fects data that serve as the POD are from hu-
man studies, then the UF would not need to 
address this area of uncertainty.
 • Human variability in sensitivity: If chem-
ical-specific data are available to help deter-
mine the magnitude of the variability in hu-
man sensitivity, then such data are used to 
refine the size of the final UF. If health effects 
data that serve as the POD are from a sensi-
tive human group (e.g., non-smoking, young 
adult females for a clinical study of nasal irri-
tation [Shusterman et al. 2003]), then the UF 
would be smaller in addressing this area of 
uncertainty. Because IDLH values are used in 
occupational applications, the range of vari-
ability that needs to be covered in applying 
the UF is expected to be less than for develop-
ment of exposure values/limits meant to pro-
tect sensitive members of the general public. 
Conversely, if additional data do not include 
sensitive populations (e.g., asthmatics who 
may be exposed to respiratory irritants), then 
a larger UF may be selected. 
 • Severity of effect: The size of the adjustment 
needed would reflect the severity of effect ob-
served at the POD. This is reflected in the pre-
liminary UF ranges shown in Table 4–1. For 
example, as shown in the table, to derive an 
IDLH value that protects from severe effects, 
a larger margin would be needed between an 
LC50 value and the IDLH value than would be 
needed in between a BMCL05 for an escape-
impairing effect and the IDLH value. The 
range of preliminary values incorporates this 
consideration of effect severity.
The consideration of the severity of effect also 
addresses the slope of the concentration– 
response curve. Steep concentration–response 
curves and high-quality data may result 
in UFs at the lower end of the range. Steep 
concentration–response curves represent 
estimates of responses that decrease rapidly 
with decreasing exposure concentrations, so 
that a smaller UF may be warranted to reach 
the response level in the concentration– 
response curve, compared with a more shal-
low concentration–response curve. Thus, if 
the concentration–response curve is very 
steep, a factor of 10 (rather than the prelimi-
nary UF of 30) may be applied to an LC50 
value, based on consideration of the overall 
database. This is because there is less than a 
factor of 3 between the LC50 and the (actual 
or estimated) LC01 value.
 • Duration of exposure: For most acute lim-
its, including IDLH values, acute studies are 
typically used directly as the basis for the 
POD. Thus, the available studies are gener-
ally representative of the overall duration of 
interest (exposure for a single day or less). 
Further refinements to account for uncer-
tainties in duration extrapolation, such as 
between a 4-hour study and the 30-minute 
duration of interest for IDLH development, 
are addressed in the time-scaling adjustment 
to the POD (see Section 3.5), rather than as 
a consideration for the UF value. However, 
significant uncertainties may need additional 
consideration if the available study is limited 
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in design or outside the immediate duration 
range of interest. For example, if only repeat-
exposure studies were available for a chemi-
cal to serve as the POD, and the observed ef-
fects were not clearly due only to initial acute 
exposures, then the use of such a POD might 
justify a smaller UF.
 • Other database deficiencies: A UF at the 
higher end of the typical range (e.g., a UF of 
10 instead of 3) is often used if major uncer-
tainties or additional significant concerns are 
identified. If a database is very deficient, then 
the UF might be increased. This approach is 
often used if the only reliable data are lethality 
data from a single acute study. Other consid-
erations for database deficiency relate to the 
potential for effects that were not evaluated in 
the available studies. For example, the higher 
end of the range may be used if the data indi-
cate that the chemical is a sensory irritant and 
the data are insufficient to derive an IDLH 
value (e.g., due to inappropriate exposure du-
rations) but indicate a large margin between 
concentrations causing severe irritation and 
those causing death. Other data gaps that may 
affect the size of the final UF reflect specific 
endpoints of concern. For example, a UF from 
the higher end of the range may be used if a 
chemical is a known or likely carcinogen or 
a developmental toxicant, with evidence that 
acute exposures may be of concern. 
The examples in Appendix A highlight how these 
weight-of-evidence considerations are applied to 
select UFs and derive potential IDLH values. 
4.3  Research Support for  
the NIOSH Uncertainty 
Factor Approach
The UF approach used for deriving IDLH values 
is based on a review of NIOSH research efforts, 
approaches used by other organizations that es-
tablish acute exposure limits/values, and other 
independent research. 
The NIOSH approach is similar to that of other 
agencies in terms of the areas of uncertainty ac-
counted for in determining the appropriate value of 
the final UF. Although the NIOSH approach does 
not assign an individual factor for each area of un-
certainty, there is generally good agreement between 
the NIOSH UF and the UF embedded in deriva-
tion of AIHA ERPG values and the cumulative UF 
used for derivation of the AEGL values. As expected, 
there is not complete alignment between these val-
ues, because of differences in application of IDLH 
values versus other types of acute exposure limits. 
In particular, the UF applied to the IDLH value is 
often smaller than for deriving the ERPG or AEGL 
values, which results in a larger final exposure limit 
for IDLH values compared to these other guidelines. 
For example, differences often arise because of the 
explicit inclusion of potentially sensitive members 
of the general population (e.g., children, elderly, and 
individuals with health impairments) during the es-
tablishment of community-based acute exposure 
limits, such as the ERPG and AEGL. The IDLH 
values do not take into consideration the poten-
tially sensitive members of the general population 
because it is assumed that they will not be sub-
stantially represented in the workforce for the pur-
poses of considering average population responses. 
However, in some cases such populations may be 
considered when a chemical has specific effects on 
a target population that is well-represented in the 
expected worker population. An example would be 
an agent that has significant impacts on asthmatics. 
In such cases, health effects data from asthmatics 
that have been exposed to the agent would be ap-
propriate for defining the POD as the basis for de-
riving an IDLH value.
To further verify that the preliminary ranges of the 
UF are supported by existing data, NIOSH con-
ducted an analysis of acute toxicity data to deter-
mine the appropriate size of the UF for extrapolat-
ing from various points of departure to derive IDLH 
values that would be expected to protect from le-
thal, severe, irreversible, or escape-impairing effects 
in humans. Two approaches were used: one based 
on a detailed evaluation of acute toxicity data for 
20 chemicals, and the second based on data for 94 
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chemicals taken from the documentation for IDLH 
values and consideration of MOA. 
From these data compilations for chemicals with 
robust datasets, the ratios between animal lethality 
values commonly used as the POD for developing 
the IDLH value (e.g., LC50 values) and the effect level 
for lethality or other non-lethal effects in humans 
were determined for each chemical. The distribu-
tion of these ratios was analyzed, and the median 
value and 95th percentile value for each comparison 
were derived (see Appendix D). The resulting me-
dian values and upper-bound estimates for these 
case study chemicals were used to verify that the 
range of total UFs adopted in the IDLH methodol-
ogy adequately accounts for the value that should 
be applied to an animal-based endpoint to protect 
from severe or escape-impairing effects in humans. 
The analysis found that animal lethal concentra-
tions and human effect thresholds (both LCLO val-
ues and LOAELs for severe or escape-impairing 
effects) were generally correlated, such that chem-
icals with low animal LC50 values tended to have 
low human lethality thresholds and cause severe 
or escape-impairing effects in humans at low con-
centrations. This finding was important to support 
the approach of developing preliminary UF ranges 
that could be used to address protection from non-
lethal effects when extrapolating from data from 
acute animal studies. Additional analyses were 
conducted by MOA category (e.g., irritant, CNS 
depressant, or “other”) to determine if different UF 
ranges could be applied on the basis of a chemical’s 
MOA. However, statistically significant differences 
were not found among the MOA categories. Thus, 
this further refinement to the approach for devel-
oping a preliminary UF to address effect severity by 
MOA category has not been applied for IDLH deri-
vation. Overall, comparison of the median values 
to the UF ranges in Table 4–1 showed that the most 
common value is typically above or in the range 
of the median value for the comparison dataset. 
This result is also consistent with other evaluations 
that analyzed effect-level ratios from acute toxicity 
studies (e.g., Rusch et al. 2009). Additional results, 
as well as the results of the second approach, are 
presented in Appendix D.
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APPENDIX A: Example of the Derivation 
of an IDLH Value
This appendix illustrates the IDLH value deriva-
tion on the basis of the scientific criteria outlined in 
this document. This profile contains the proposed 
IDLH value and draft support documentation for 
chlorine (CAS# 7782-50-5). It should be noted 
that the information presented in this appendix is 
intended to serve only as an illustration of the ap-
plication of the derivation process outlined in this 
CIB. For this reason, the proposed IDLH value for 
chlorine presented in this CIB should not be con-
strued as official NIOSH policy.
A.1  Support Documentation  
for the Revised IDLH  
Value for Chlorine 
Revised IDLH value: 2.8 ppm (8.1 mg/m3)
Basis for revised IDLH value: The IDLH value is 
based on the human LOAEL for severe effects, on 
the basis of respiratory irritation and cough in hu-
man volunteers exposed to 2 ppm for 1 hour [An-
glen 1981]. The LOAEL was adjusted to a 30-minute 
duration equivalent value of 3 ppm. A UF of 1 was 
applied to account for extrapolation from a thresh-
old for severe effects in humans, yielding an IDLH 
value of 2.8 ppm rounded to 3 ppm.
1994 IDLH value: 10 ppm
Basis for 1994 IDLH value: The 1994 IDLH value 
for chlorine is 10 ppm, based on acute inhalation 
toxicity data in humans [NIOSH 1994]. 
NIOSH REL: 0.5 ppm (1.45 mg/m3), 15-minute ceiling 
[NIOSH 2005]
Current OSHA PEL: 1 ppm (3 mg/m3), ceiling 
[OSHA 2010]
1989 OSHA PEL:‡ 0.5 ppm (1.5 mg/m3), TWA; 
1 ppm (3 mg/m3), STEL [OSHA 1989]
2010 ACGIH TLV: 0.5 ppm, TWA; 1 ppm, STEL 
[ACGIH 2010]
2010 AIHA ERPG: ERPG-1: 1 ppm; ERPG-2: 
3 ppm; ERPG-3: 20 ppm [AIHA 2010]
2010 AIHA WEEL: Not available
Description of substance: A greenish yellow gas 
with a pungent, irritating odor [NAS 2004]
LEL: Not available
NAC AEGL: Summarized in Table A–1. National 
Advisory Committee [2004] Final AEGLs: Chlorine. 
A.2  Animal Toxicity Data
The available acute lethality database consists of 
multiple studies in mice [Lipton and Rotariu 1941; 
Silver et al. 1942; Schlagbauer and Henschler 1967; 
Bitron and Aharonson 1978; Alarie 1980; Jiang et al. 
1983; O’Neil 1991], rats [Weedon et al. 1940; Back 
et al. 1972; MacEwen and Vernot 1972; Vernot et 
al. 1977; Zwart and Woutersen 1988], rabbits [Bar-
row and Smith 1975], and dogs [Underhill 1920; 
Withers and Lees 1985a]. The lowest LC50 value in 
animals was identified from a study that exposed 
mice to 127 ppm for 30 minutes [Schlagbauer and 
Henschler 1967]. Critical animal lethality data are 
‡1989 PELS are no longer legally enforced by federal 
OSHA, but many of these PELs were adopted by state 
OSHA plans, thus the 1989 PELs may still be in force 
in various states.
46 NIOSH CIB 66 • Derivation of Immediately Dangerous to Life or Health (IDLH) Values
Table A–1. Summary of the AEGL values for chlorine































Abbreviation: mg/m3 = milligrams per cubic meter; ppm = parts per million











Mouse Schlagbauer and Henschler [1967] 127 30 127 30 4.2
Mouse Zwart and Woutersen [1988] 504 30 504 30 17
Rat Zwart and Woutersen [1988] 703 30 703 30 23
Abbreviation: LC = lethal concentration; LC50 value = median lethal concentration; ppm = parts per million; UF = uncertainty factor.
*No time adjustment was made to LC50 values.
†The selection of the UF for chlorine was based on Chapter 4.0: Use of Uncertainty Factors. The UF of 30 was selected on the basis  
of (1) the extrapolation from a concentration that is lethal to animals, (2) animal to human differences, and (3) human variability.
‡Derived values are calculated by dividing the Adjusted 30-minute LC by the UF.
Table A–3. Acute toxicity data and 30-minute-equivalent 












Mouse Jiang et al. [1983] 9.1 360 32 10 3.2
Rat Jiang et al. [1983] 9.1 360 32 10 3.2
Abbreviation: LOAEL = lowest observed adverse effect level; ppm = parts per million; UF = uncertainty factor.
*For exposures other than 30 minutes, the ten Berge et al. [1986] relationship is used for duration adjustment (Cn × t = k); no 
empirically estimated n values were available; therefore, the default values were used: n = 3 for exposures greater than 30 
minutes and n = 1 for exposures less than 30 minutes.
†The selection of the UF for chlorine was based on Chapter 4.0: Use of Uncertainty Factors. The UF of 10 was selected on the  
basis of (1) animal to human differences, and (2) human variability.
‡Derived values are calculated by dividing the Adjusted 30-minute LC by the UF.
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summarized in Table A–2, along with time adjust-
ments, UF, and potential derived IDLH values. 
Non-lethal effects in mice, rabbits, and rats consisted 
of ocular and nasal irritation, transient changes in 
lung function, bronchitis, lesions in the nasal pas-
sages and lung, and mild edema [Barrow and Smith 
1975; Jiang et al. 1983; Zwart and Woutersen 1988; 
Demnati et al. 1995]. Nasal lesions appear to be the 
most sensitive effect, as they occur at the lowest 
tested concentrations of chlorine in both rats and 
mice [Jiang et al. 1983]. Multiple RD50 studies have 
also been conducted in mice [Barrow et al. 1977; 
Barrow and Steinhagen 1982; Chang and Barrow 
1984; Gagnaire et al. 1994]. Critical animal non-
lethality data are summarized in Table A–3 along 
with time adjustments, UFs, and potential derived 
IDLH values. 
A.3  Human Data
Deaths have been reported after inhalation expo-
sures to chlorine, but specific exposure concentra-
tions are not available from reports of accidental 
releases. Withers and Lees [1985b] estimated 
lethal concentrations to humans using a probit 
analysis of available information. They estimated 
a 30-minute LC50 value and LC10 value of 100 and 
50 ppm, respectively, for vulnerable populations. 
Critical human lethality data are summarized in 
Table A–4, along with time adjustments, UFs, and 
potential derived IDLH values.
Experimental exposure to non-lethal concentrations 
of chlorine has caused changes in nasal air resistance 
[D’Alessandro et al. 1996; Shusterman et al. 1998], 
transient changes in pulmonary function [Anglen 
1981; Rotman et al. 1983; D’Alessandro et al. 1996], 
irritation [Joosting and Verberk 1974; Anglen 1981; 
Rotman et al. 1983], and cough [Joosting and Ver-
berk 1974; Anglen 1981]. The lowest concentration 
at which mild discomfort due to irritation or cough 
was reported is at 1 ppm for durations of 4 hours or 
greater [Anglen 1981; Rotman et al. 1983]; however, 
irritation was not significant among volunteers ex-
posed to 2 ppm for 30 minutes [Anglen 1981].
Multiple accidental exposures to non-lethal con-
centrations of chlorine have been reported, but 
specific exposure conditions and durations are not 
available. Symptoms of dyspnea, cough, and irrita-
tion are most commonly reported in the literature 
[Shroff et al. 1988; Abhyankar et al. 1989; Mrvos et 
al. 1993; ILO 1998], but other severe systemic ef-
fects (such as headache, vomiting, giddiness, chest 
Table A–4. Acute toxicity data and 30-minute-equivalent  









30-Minute derived value 
(ppm)‡
Human Withers and Lees [1985b] 50 30 50 3 17
Abbreviation: LC = Lethal concentration; LCLO = lowest lethal concentration of a substance in the air reported to cause death; 
ppm = parts per million; UF = uncertainty factor.
*No time adjustment was made to the LCLO value. 
†The selection of the UF for chlorine was based on Chapter 4.0: Use of Uncertainty Factors. The UF of 3 was selected  
on the basis of human variability.
‡Derived values are calculated by dividing the Adjusted 30-minute LC by the UF.
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pain, and abdominal discomfort) have also been 
reported [Shroff et al. 1988; Abhyankar et al. 1989]. 
Critical human non-lethality data are summarized 
in Table A–5, along with time adjustments, UFs, 
and potential derived IDLH values. 
A.4  IDLH Value  
Rationale Summary
Among the acute lethality studies, the mouse 
provides the lowest LC50 value of 127 ppm for a 
30-minute exposure period [Schlagbauer and Hen-
schler 1967]. A UF of 30 was applied to account for 
extrapolation from a concentration that is lethal to 
animals, animal to human differences, and human 
variability, resulting in a potential IDLH value of 
4.2 ppm. Anglen [1981] reported a LOAEL of 2 
ppm for throat irritation and cough in human vol-
unteers exposed to chlorine for 1 hour. The LOAEL 
was duration-adjusted to a 30-minute-equivalent 
value of 2.8 ppm. A safety factor of 1 was applied 
to account for extrapolation from a threshold for 
irritant effects in humans, resulting in an IDLH 
value of 3 ppm rounded to 3 ppm.. This value is 
supported by the presence of irritant effects in hu-
man volunteers exposed to 1 ppm of chlorine for 
4 hours [Anglen 1981; Rotman et al. 1983], which 
would also result in a similar IDLH value.
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Table A–5. Acute toxicity data and 30-minute-equivalent  














Human Anglen [1981] 2.0 30 2.0 1 2.0
Human Anglen [1981] 2.0 60 2.8 1 2.8
Human Rotman et al. [1983] 1.0 240 2.8 1 2.8
Human ILO [1971] 40.0 30 40 3 13
Abbreviation: LC =lethal concentration; LOAEL = lowest observed adverse effect level; NOAEL = no observed adverse effect level; 
ppm = parts per million; UF = uncertainty factor
*For exposures other than 30 minutes, the ten Berge et al. [1986] relationship is used for duration adjustment (Cn × t = k); no 
empirically estimated n values were available; therefore, the default values were used: n = 3 for exposures greater than 30 
minutes and n = 1 for exposures less than 30 minutes.
†The selection of the UF for chlorine was based on Chapter 4: Use of Uncertainty Factors. The UF of 1 or 3 was selected on the basis 
of (1) severe effects or (2) human variability.
‡Derived values are calculated by dividing the Adjusted 30-minute LC by the UF.
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APPENDIX B: IDLH Value  
Development Prioritization
This appendix identifies how NIOSH will deter-
mine the priorities for developing IDLH values. 
The guidance values play an important role in plan-
ning work practices surrounding potential high-
exposure environments in the workplace and in 
guiding actions by emergency response personnel 
during unplanned exposure events. Ideally, IDLH 
values would be available for all chemicals that 
might be present under high exposure situations. 
However, this breadth of coverage of IDLH values 
is not practical and might not even be necessary for 
many chemicals, such as those with very low expo-
sure potential or those that are not acutely toxic. In 
addition, the absence of data and limited resources 
makes it difficult to evaluate the multitude of chemi-
cals currently available in commerce. Therefore, a 
prioritization process is used by NIOSH to ensure 
that resources are allocated to yield the greatest im-
pact on risk reduction in the event that control mea-
sures fail (including respiratory protection devices). 
This process takes into account both toxicity and ex-
posure potential, and it is applied to a broad pool of 
relevant chemicals (e.g., chemical warfare agents, in-
dustrial chemicals, high-production-volume [HPV] 
chemicals, or agrochemicals subject to emergency 
or uncontrolled releases). A qualitative algorithm is 
used to generate a tentative relative priority rank-
ing. This process is intended only to provide tenta-
tive guidance based on a simple approach that uses 
readily available sources of information. The result-
ing priorities are further modified on the basis of 
NIOSH emphasis areas. For example, chemicals 
can be added or removed from the list on the basis 
of new information related to toxicity or exposure 
potential. The development and use of a docu-
mented prioritization process allows for frequent 
updating of both input data and prioritization cri-
teria to meet changing needs. 
Substances considered in the ranking process are 
compiled from existing databases of chemicals 
identified by other agencies as “of concern” because 
of use in chemical terrorism or as chemicals with 
the potential for exposure due to other uncon-
trolled releases (and thus having greater opportu-
nities for high, acute exposures). Existing lists of 
agents of concern may not be fully representative 
of industrial chemicals for which acute exposures 
may occur during planned activities (e.g., spe-
cial maintenance activities) or unplanned-release 
events. However, IDLH values for many of these 
sorts of chemicals were included in the original 
IDLH value development process and in the 1994 
updates. Moreover, NIOSH adds additional chemi-
cals of interest that are nominated by interested 
stakeholders or the subject of new emphasis pro-
grams. Chemicals from the following databases 
(as supplemented by NIOSH chemicals of interest) 
were included in the ranking process: 
 • Hazardous Substances Emergency Events 
Surveillance (HSEES)—This database con-
tains self-reported incidents of accidental 
chemical releases. The database was created 
by the Agency for Toxic Substances and Dis-
ease Registry (ATSDR) [ATSDR 2008].
 • Emergency Preparedness and Response—
This list of specific agents and other threat 
agents was created by the Centers for Disease 
Control and Prevention (CDC) [CDC 2008].
 • Emergency Response Guidebook (ERG)—
This list of toxic by inhalation (TIH) chemi-
cals and water-reactive TIH chemicals was 
created by the DOT [US DOT 2008]. 
 • Chemical Facility Anti-Terrorism Standards 
(CFATS), Appendix A—This list of chemicals 
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of interest to national security was created 
by the Department of Homeland Security 
(DHS) [US DHS 2007].
Exposure-related parameters can be divided into two 
categories: 1) those that provide a direct indication 
of exposure potential (e.g., number of recorded ac-
cidents or spills involving a chemical) and 2) data 
that provide indirect indication of exposure potential 
(e.g., volume produced). In weighing such metrics, a 
balance needs to be struck between the greater confi-
dence provided by direct-release data based on the 
obvious relevance to exposure potential, and the 
need to have data on exposure potential that are 
available for most chemicals. Information on direct 
exposure indicators was obtained from the HSEES 
database [ATSDR 2008]. Although only 14 states 
participate in the program, the data are useful as 
an exposure indicator. Evidence of frequent past 
incidents involving uncontrolled releases receives 
a score of 1, and the absence of reporting of prior 
releases is scored 0. 
Chemical production volume is used as an indirect 
indication of exposure potential [USEPA 2008]. The 
USEPA classifies HPV chemicals as those chemi-
cals produced or imported in the United States in 
quantities of 1 million pounds or more per year; 
medium-production chemicals are quantities of 
25,000 to less than 1 million pounds per year; and 
low-production chemicals are quantities less than 
25,000 pounds per year. HPV chemicals receive a 
score of 1, whereas low-and medium-production-
volume chemicals receive a score of 0.
Because the aim of the prioritization process is the 
development of guidance for protection from acute 
inhalation exposures, endpoints that best inform 
the potential for life-threatening, irreversible, or 
escape-impairing effects following acute inhalation 
exposures receive the greatest weight. The follow-
ing approach and resources are used to score toxic-
ity considerations:
1. Direct indication of exposure potential (e.g., 
number of recorded accidents or spills involving 
a chemical).
 • Evidence of frequent past incidents involving 
uncontrolled releases
 • HSEES—collects and analyzes actual haz-
ardous chemical releases and emergency re-
sponder injuries
 • Chemicals with uncontrolled releases (URs) 
are scored as a 1, and lack of reported data is 
scored as a 0.
2. Indirect indication of exposure potential (e.g., 
volume produced)
 • Indicative of the potential for exposure from 
the amount of chemical that is produced
 • USEPA classifies chemicals as low, medium, 
or high production volume (HPV)
 • Chemicals classified as HPV are scored as a 1, 
whereas low- and medium-volume chemicals 
are scored as a 0.
3. Short-term exposure limits (STELs)—NIOSH 
RELs, OSHA PELs, AIHA WEELs, and ACGIH 
TLVs® [ACGIH 2008; AIHA 2008; NIOSH 2007]
 • STEL values below 20 ppm for vapors and 
gases or 2 mg/m3 for particulates provide a 
reasonable cut point for identifying the most 
significantly acutely toxic substances.
 • Substances with a STEL below these cut points 
receive a score of 1, whereas substances with a 
STEL equal to or greater than these values or 
that have no available STEL receive a score of 0.
4. Irritant Potential (IRR)—NIOSH Pocket Guide 
to Chemical Hazards [NIOSH 2005] or the Eu-
ropean Union (EU) Risk Phrases (R-phrases) 
[EU 2008] for irritation 
 • Irritants receive a score of 0.5 and corrosive 
chemicals receive a score of 1; all other chem-
icals receive a score of 0.
5. Acute toxicity (AT) (e.g., lethal concentration 
resulting in 50% mortality in exposed animals 
[LC50])—Registry of Toxic Effects of Chemical 
Substances (RTECS) [CCOHS 2008]
 • Chemicals classified as extremely or highly 
hazardous in RTECS or with an EU R-phrase 
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of “very toxic” or “toxic” are scored as 1; oth-
erwise, chemicals are scored as 0. 
 • Chemicals that have not been evaluated by 
means of these systems are judged on the ba-
sis of the lowest reliable LC50 compared to the 
EU R-phrase criteria.
6. Developmental toxicant (DT)—NIOSH Pocket 
Guide to Chemical Hazards [NIOSH 2005] or 
California Environmental Protection Agency 
(Cal/EPA) Proposition 65 list [Cal/EPA 2008].
 • Chemicals identified as reproductive/devel-
opmental toxicants are scored as 0.5; other-
wise, chemicals are scored 0.
7. Carcinogenicity (CA)—EPA, International Agency 
for Research on Cancer (IARC) [IARC 2008], 
ACGIH [2008], NIOSH Pocket Guide to Chemical 
Hazards [NIOSH 2005], Cal/EPA Proposition 65 
List [Cal/EPA 2008], or other sources
 • Chemicals classified by recognized systems 
as probable, likely, or known human carcino-
gens are scored as 0.5; otherwise, chemicals 
are scored as 0.
8. Other considerations are used qualitatively to 
further refine priorities among chemicals with 
the same risk-based score. These Tier II consid-
erations include the following:
 • Availability of other acute exposure guid-
ance—Such guidance includes existing 
IDLH, AEGL, or ERPG values. The availabili-
ty of such guidance decreases the urgency for 
developing (or revising) IDLH values.
 • Availability of toxicity data—the absence of 
adequate data precludes the development of 
an IDLH value. The lack of toxicity data for a 
chemical with high exposure potential is used 
to identify research needs.
 • Availability of exposure monitoring meth-
ods —The availability of a validated sampling 
and analytical method increases the likely 
near-term utility of a derived IDLH value. 
The absence of a validated sampling and ana-
lytical method for high-priority chemicals 
could be used to identify research needs. 
 • Presence on existing lists of high priority 
agents—If other agencies have listed the mate-
rial as a high priority, then the IDLH value may 
be useful to other agencies. This type of lever-
aging of resources is desirable and also helps to 
harmonize levels of worker health protection 
among agencies with related missions.
 • Degree of safety hazard—If potential risk for 
two or more chemicals as determined on the 
basis of chemical toxicity is equal, then agents 
that have a greater degree of safety-related risk 
(e.g., flammability) are given greater weight. 
This consideration allows for easier compari-
son of overall risk profiles and selection of the 
most appropriate basis for risk management 
(e.g., developing entry criteria or emergency 
plans on the basis of whichever is the greater 
concern, safety or health risk).
The overall priority score is the sum of the exposure 
score and toxicity score: 
 • Tier I: Risk Priority Score = Exposure Score 
[ranges from 0 to 2] + Toxicity Score [ranges 
from 0 to 3]
Risk Priority Score =  
   [UR + PV] + [STEL + IRR + AT + DT + CA]
Where:
   AT = acute toxicant
   CA = carcinogenicity
   DT = developmental toxicant 
   IRR = irritant
   PV = production volume
   STEL = short-term exposure limit
   UR = uncontrolled release 
 • Tier II: Used qualitatively to make an overall 
judgment on priorities among chemicals with 
the same risk priority score.
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APPENDIX C: Critical Effect Determination for IDLH 
Value Development—Consideration of Severity, 
Reversibility, and Impact on Escape Impairment 
As discussed in the main document, the intent of the 
IDLH value is to protect against exposures that are 
“likely to cause death or immediate or delayed per-
manent adverse health effects or prevent escape from 
such an environment.” In other words, the most ap-
propriate effects to use as the basis of the IDLH value 
derivation are those that are severe, irreversible, or 
escape-impairing. Scientific judgment is an important 
aspect in evaluating severity of effects and determin-
ing which ones are irreversible, but guidance is avail-
able from a number of different sources. 
Severe adverse effects that are not necessarily im-
mediately escape-impairing are judged on a case-
by-case basis weighing considerations such as the 
need for medical treatment, the potential for altered 
function or disability, and the potential for long-
term deficits in function. These include severe, but 
reversible, acute effects such as hemolysis, chemical 
asphyxia, delayed pulmonary edema, and signifi-
cant acute organ damage (hepatitis, decreased kid-
ney function, etc.). If these effects could be caused 
by the chemical, it is important that the available 
toxicity studies evaluated the development of such 
effects by, for example, allowing sufficient time be-
tween exposure and evaluation of the endpoint.
Guidance on evaluating and ranking the sever-
ity of toxic effects is available from a number of 
organizations. DeRosa et al. [1985] developed 
a 10-category scheme for evaluating noncancer 
toxicity in the evaluation of Reportable Quantities 
under the USEPA Superfund legislation. Although 
designed for the context of chronic exposures, this 
approach provides insight into the relative severity 
of different types of histopathology and develop-
mental toxicity. The Agency for Toxic Substances 
and Disease Registry (ATSDR) includes the follow-
ing five severity rankings [Pohl and Abadin 1995]:
 • No Observed Effect Level (NOEL)
 • No Observed Adverse Effect Level (NOAEL) 
 • Minimal Lowest Observed Adverse Effect 
Level (LOAEL1) 
 • Moderate Lowest Observed Adverse Effect 
Level (LOAEL2) 
 • Frank Effect Level (FEL)
ATSDR applies this approach from acute expo-
sures (defined as exposures up to 14 days) through 
chronic exposures, and a number of publications 
are available on applying this approach to vari-
ous types of effects (e.g., Abadin et al. 1998, 2007; 
Chou and Pohl 2005; Pohl and Chou 2005; Pohl 
et al. 2005). Although intended for a different 
purpose, these analyses can provide insights into 
the evaluation of effect severity. In particular, the 
“moderate” LOAEL category used by ATSDR is 
more likely to be considered severe or irreversible, 
and thus relevant to IDLH value development. 
Guidance on evaluation of the severity of effects 
is also available from the USEPA RfC guidelines 
[USEPA 1994] and from the American Thoracic 
Society (e.g., Pellegrino et al. 2005). 
Determining which effects are escape-impairing is 
complicated both by the limited guidance available 
from other sources and by the fact that reporting of 
signs and symptoms for similar underlying effects 
may differ across human and animal studies. For 
example, the same underlying mechanism may be 
described as inducing intolerable irritation in a hu-
man clinical study or case report, but may manifest 
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as changes in respiration rate, nasal discharge, or al-
tered activity level in an acute toxicity test in animals. 
For this reason, guidance was developed that allows 
for more consistent assigning of comparative sever-
ity of observed effects (i.e., escape-impairing versus 
non-escape-impairing) for commonly observed ad-
verse effects used as the basis of IDLH values. Table 
C–1 provides guidance for classification of many 
effects commonly seen in acute studies. Because of 
the nature of the evaluation methods, endpoints that 
can be evaluated in humans are generally limited to 
clinical signs and symptoms, along with some spe-
cialized testing, and some histopathology evaluation 
that can be conducted non-invasively (e.g., for the 
nasal cavity), or can be inferred from other evalua-
tions (e.g., pulmonary edema).
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APPENDIX D: Analyses Supporting the 
Development of Uncertainty Factor Approach
During the 1994 update to the IDLH values, NIOSH 
chose to use an approach for extrapolation from a 
duration-adjusted LC value (e.g., LC50 value) that 
included the use of a default UF (or safety factor) of 
10. When data on effects other than lethality were 
available, an unspecified UF less than 10 was typi-
cally applied. The rationale for this decision was 
neither described in the 1994 update methodology 
[NIOSH 1994] nor specified in the support docu-
mentation for the IDLH values derived from such 
data. This has resulted in the need to re-examine 
this practice to verify its efficacy in the derivation 
of health-protective IDLH values. 
To evaluate the assignment of UFs, NIOSH con-
ducted several analyses in preparation of the IDLH 
methodology to determine if the approach used 
in the 1994 update needed to be revised. Numer-
ous datasets were evaluated to identify the typi-
cal ratio between the IDLH and the POD derived 
from different types of studies. The results of these 
analyses are presented in Section D.1. In arriving at 
the final methodology presented in this CIB, the 
empirical analysis discussed in this appendix was 
supplemented by previously published data analy-
sis [Fowles et al. 1999; Rusch et al. 2010]. Current 
risk assessment principles related to the rationale 
and concepts for UF application for setting exposure 
guidelines of different types were also considered, in 
particular the process used by the AEGL committee.
D.1  Analysis for  
Selected Approach
To derive a scientifically based approach for the use of 
UFs in the derivation of IDLH values, several analy-
ses were conducted to determine the appropriate size 
of the UF for extrapolating from various points 
of departure, taking into account the weight-of- 
evidence approach and MOA considerations de-
scribed previously. Two approaches were used. 
Approach 1 involved a detailed evaluation of 
acute toxicity data for a selection of 20 chemicals, 
whereas Approach 2 evaluated the MOAs identi-
fied from a larger dataset of 94 chemicals. 
For Approach 1, 20 case-study compounds with 
high-quality animal lethality studies and adequate 
human effects data to estimate lethality thresholds 
were identified. The Log-Probit model of USEPA’s 
BMDS was used to calculate the LC50 and LC01 val-
ues based on the mortality incidence data for each 
of the animal studies of adequate quality. All of the 
animal LC50 values and human lethality threshold 
data were adjusted to 30-minute-equivalent values 
via the method of ten Berge and colleagues [ten 
Berge et al. 1986], by using chemical-specific val-
ues of n for lethality whenever possible or standard 
defaults (i.e., n = 1 for extrapolation from shorter to 
longer durations and n = 3 for extrapolation from 
longer to shorter durations), and using an n of 1 for 
time correction of human effects other than lethal-
ity (e.g., irritation or signs of CNS depression). It 
should be noted that the default ten Berge adjust-
ment approach would also be most appropriate for 
less than lethal effects. However, since this analy-
sis was intended as one of several range-finding 
approaches for uncertainty selection explored by 
NIOSH, the additional analysis required to make 
the adjustments from the poorly documented hu-
man studies was deemed an unnecessary refinement 
for this particular analysis. The default ten Berge ap-
proach is specified for lethal and non-lethal effects 
within the IDLH methodology outlined in this CIB. 
The correct approach for extrapolation is uncertain 
for less-than-lethal effects. Adequate quantitative 
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data are rarely available for severe adverse effects 
in humans to support concentration–response 
modeling. In particular, thresholds for lethality 
are difficult to estimate from the very limited 
available case report information. However, 
available effect levels in humans gleaned from 
peer-reviewed secondary sources were arrayed by 
concentration (Conc), duration of exposure (time, 
t), the concentration × duration product (Conc × 
t = k), and severity of effect for each study that 
provided human response data.
Results of this analysis are shown in Table D–1. 
The analysis found that animal lethal concentra-
tions and human effect thresholds were generally 
correlated for this limited dataset. Additional anal-
yses were conducted by MOA category (e.g., irri-
tant, CNS depressant, or “other”). Group means 
for each MOA category were not significantly dif-
ferent when comparing animal lethal concentra-
tions (LC50 and LC01 values) to human lethality 
thresholds (human LCLO values). However, group 
means for the three MOA categories did differ sig-
nificantly for the ratios of animal lethal concen-
trations (LC50 and LC01 values) versus the human 
LOELs for the 20 case-study chemicals. The mean 
LC50/human LOEL ratio was greatest for irritants, 
followed by chemicals that induce CNS effects, 
and then chemicals that had other MOAs.
As shown below in Table D–1, comparison of ani-
mal RD50 values to IDLH values suggests that, on 
average, the RD50 corresponds to a human severe 
irritation threshold, since the IDLH values used 
in the analysis were based on irritant effects in hu-
mans. This interpretation is consistent with study 
findings [Schaper 1993] that suggested that ex-
posure at the RD50 would likely cause intolerable 
sensory irritation. However, it is noteworthy that 
the RD50 would have been considered in the over-
all weight of evidence in setting the IDLH values 
used in our analysis, which might have biased the 
results toward a value of 1. 
Table D–1. Ratio of lethal concentrations from  
animal studies and observed or estimated human effect levels










Abbreviation:  IDLH = immediately dangerous to life or health;  LC01  = the statistically derived air concentration that 
caused lethality in 1% of test animals;  LC50 = median lethal concentration; LCLO = lowest lethal concentration of a 
substance in the air reported to cause death;  LOEL = lowest observed effect level; RD = respiratory depression.
*Based on analysis of 20 case study substances. The numerator is the value from animal studies and the denominator  
is the human effect level or value of the IDLH value.
†Based on analysis of IDLH values.
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The second approach used data directly from cur-
rent IDLH value documentation to analyze all of 
the chemicals in the current list of IDLH values 
that are based on human effects data and had at 
least one reported LC50 value, resulting in a list of 
94 chemicals for further examination. For each of 
these chemicals, the analysis identified the value of 
the lowest adequate 30-minute adjusted LC50 value, 
the current IDLH value, and the MOA for which 
the current IDLH value was set. As for the first ap-
proach, three MOA categories were used:
1. Irritation
2. Neurological effects 
3. “Other” 
It was noted that the “other” category included 
several pesticides that act via inhibition of cho-
linesterase. Although this group was not analyzed 
separately, it does form a potential fourth group for 
additional analysis. The cholinesterase inhibitors 
were not included in the general neurological ef-
fects category, since they have a specific underlying 
mechanism that might yield significant differences 
in lethality to non-lethal-effect ratios, as compared 
with other organics that act via the more general 
mechanisms of CNS depression. Published data 
were also used to compile RD50 estimates (the con-
centration of the chemical that results in a 50% de-
crease in respiratory rate in a standardized rodent 
test) for these same chemicals. 
The distribution of the LC50/IDLH value ratios is 
shown in Figure D–1. Results of the LC50/IDLH 
value ratio analysis (shown in Figure D–1) indicate 
that a factor of 10 would account for human effect 
thresholds for effects such as severe irritation and 
neurological effects, for approximately half of the 
chemicals reviewed, although a factor as high as 
100 may be needed to cover 95% of chemicals. Dis-
tribution of RD50/IDLH value ratios for 26 chemi-
cals yielded a median ratio of 1, suggesting that 
exposure at the RD50 would generally result in sen-
sory irritation of sufficient severity to be judged as 
escape-impairing. This interpretation is consistent 
with study results [Schaper 1993] suggesting that 
exposure at the RD50 would likely cause intolerable 
sensory irritation. Overall, no clear pattern regard-
ing MOA was evident when comparing LC50/IDLH 
value ratios and its primary MOA for the 94 chemi-
cals or comparing RD50/IDLH value ratios for the 
26 chemicals.
This analysis hypothesized that potent irritants 
may have a greater difference between the LC50 and 
the threshold for serious effects in humans, as com-
pared with chemicals that cause toxicity via other 
modes of action. If this hypothesis was true, then 
the implication would be that deriving an IDLH 
value from an LC50 for such chemicals would re-
quire a greater UF than would be needed for chem-
icals with other modes of action. The analysis pro-
duced mixed results, with a significant MOA effect 
observed for a subset of 20 chemicals, but not in a 
broader analysis of current IDLH values. Based on 
these results, the data are not adequate to recom-
mend a different UF by MOA category. 
D.2  Recommendation for  
Deriving IDLH Values
Three primary methods are traditionally applied 
during the development of acute emergency lim-
its, such as the IDLH values, ERPGs, and AEGLs, 
to account for uncertainty in extrapolating from a 
key study to arrive at the final value. In developing 
the IDLH methodology, three possible approaches 
were considered. 
 • Method 1—Use a weight-of-evidence ap-
proach, without specifying any default UF 
values. This would be an approach consistent 
with many volunteer groups that set acute 
occupational values (e.g., the AIHA ERPG 
committee). This approach provides for the 
greatest degree of flexibility in integrating 
all the complexities of the data, without hav-
ing to explain departures from defaults that 
might not be very meaningful in the context 
of a specific dataset. However, this approach 
generally has limitations in that it is not 
highly transparent—i.e., it is often difficult 
to “back-calculate” the basis for the final nu-
meric value.
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Lowest LC50 /Current IDLH





















LC50—Concentration to cause a 50% mortality rate in an acute toxicity study.
Irritants—The critical effect that would be the basis for an IDLH value is irritation.
CNS Depressants—The critical effect that would be the basis for an IDLH value is CNS system depression.
Other—The critical effect that would be the basis for an IDLH value arises from an MOA other than irritation or 
CNS depression.
Pesticide—The critical effect that would be the basis for an IDLH value is cholinesterase inhibition.
 
Figure D–1. The distribution of ratios of the lowest 30-minute adjusted LC50 value to the current 
IDLH value is shown for 94 substances, representing four MOA categories, to evaluate the potential 
uncertainty value that provides adequate coverage for each MOA. 
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 • Method 2—Use a preliminary composite UF 
as a starting point, based on the nature of 
the overall dataset, and communicate areas 
of uncertainty that impacted the final IDLH 
value in the rationale statement. This ap-
proach provides a data-informed starting 
point for the analysis, supported by empiri-
cal analysis (see Section D.2). The approach is 
intended to provide flexibility in UF selection 
by accounting for typical overlaps in individ-
ual UF and data hierarchies at the beginning 
of the UF selection process. This provides an 
increase in transparency over the weight-of-
evidence approach, without requiring signifi-
cant effort to explain departures from pre-
scribed defaults. This is the approach that has 
been included in the IDLH methodology.
 • Method 3—Apply a set of default UFs and re-
vise post-hoc on the basis of the dataset. This 
would be an approach similar to that used to 
derive the AEGL values. This approach assigns 
default values for well-defined areas of uncer-
tainty that pertain to a specific dataset. The final 
UF is derived by multiplying the individual fac-
tors. This approach is the most clear in terms of 
transparency (i.e., ability to back-calculate the 
derived value). However, because of the nature 
of the datasets involved, application of default 
values often yields conflicting or inappropri-
ate values from one potential critical study 
to another. The end result of such data con-
flicts is the application of a post-hoc weight-
of-evidence evaluation, in which the final UF 
or critical study selected might be changed to 
align better with the overall dataset. 
Application of the three methods outlined above 
should yield similar results, with the primary dif-
ferences focusing on the level of transparency of-
fered by each approach versus the need for post-
hoc modifications. There has been a history of 
successful application of methods 1 and 3, in the 
context of acute emergency limit-setting. Method 
2 is a hybrid of the methods that attempts to incor-
porate previous data and experience tailored to the 
unique needs of the IDLH Program. Method 2 is 
recommended as a reasonable blend of providing 
transparency in the basis for an assessment, with-
out the rigid application of default values that may 
require extensive post-hoc explanations. Multi-
plication of default UF values may also tend to 
yield IDLH values that are more than adequately 
protective. In developing the approach, it was 
considered that setting IDLH values lower than 
needed can present new safety risks in the context 
of the intended application as a tool for respira-
tory protection selection. 
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APPENDIX E: Quantitative Adjustments during 
the Derivation of IDLH Values
This appendix provides supplemental information 
on quantitative adjustments applied within the 
IDLH methodology. Section E.1 discusses consid-
erations applied when route-to-route extrapolation 
is conducted during the derivation of an IDLH 
value. Section E.2 provides supplemental detail 
pertaining to adjustments made during the time 
scaling of data.
E.1  Inhalation Volume  
Adjustments Approach  
for Route-to-Route  
Extrapolation
During the 1994 update of the IDLH values, a vol-
ume of 10 m3 for inhaled air was included in the 
methodology as the basis for calculating the inhala-
tion equivalent concentration from an oral toxicity 
study dose. This value represents the volume of air 
assumed to be inhaled over the course of a typical 
8-hour shift at light work load. The IDLH methodol-
ogy uses an alternative approach that takes into ac-
count that IDLH values are intended to be based on 
a maximum exposure duration of 30 minutes. As-
suming a worker breathing rate of 50 L/min for 30 
minutes, the corresponding total inhaled volume of 
air for a scenario relevant to the IDLH would be 1.5 
m3. This volume corresponds with dosimetry guide-
lines recommended by the International Commis-
sion on Radiological Protection [ICRP 1994]. Use of 
the value 1.5 m3 in the calculation of the inhalation 
equivalent concentration from an oral toxicity study 
dose has been applied in the IDLH method as the 
default for route-to-route calculations, as discussed 
in Section 3.4.2.4. 
The inhalation concentration calculated with use 
of the 1994 methodology is built on more health-
protective assumptions (yields a lower IDLH value) 
than the IDLH methodology, and it may have re-
sulted in IDLH values that are more than adequately 
protective in some cases. The impact of this change 
in the assumed inhaled volume can be highlighted in 
the context of a typical example for a chemical with 
an IDLH value based on systemic toxicity derived 
from a single-oral-dose acute lethality study. Table 
E–1 illustrates the differences between the 1994 ap-
proach that used 10 m3 and the IDLH methodology 
presented in the CIB that uses 1.5 m3. 
Because the impact of the selected default is sig-
nificant (roughly 7-fold), additional insight into 
the conditions under which each possibility is most 
scientifically appropriate is needed. Factors that 
impact this judgment include these:
 • The toxicokinetic profile associated with the 
dosing regimen for the critical study com-
pared to the IDLH acute inhalation scenario. 
Key considerations include 1) differences 
in absorption kinetics and 2) differences in 
clearance or elimination kinetics.
 • The MOA and its associated dose metric for 
the adverse effect, commonly based on either 
peak (maximum) concentration (Cmax) or 
total dose (represented by the area under the 
curve [AUC]).
Under the most common scenarios and datasets 
available for setting IDLH values, the 1.5 m3 as-
sumption is likely to be adequate. The level of con-
cern about the degree to which the 1.5 m3 value is 
likely to be protective can be summarized for differ-
ent scenarios. If the MOA is based on the peak con-
centration, then the differences in absorption and 
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elimination rate kinetics for the dosing regimen used 
in the non-inhalation study can impact the selection 
of an inhalation volume. Simplifying assumptions 
related to the absorption rates of alternative dosing 
routes and methods can be applied to generalize the 
decision process:
 • Low Concern:
 ȣ If the underlying MOA for the critical 
effect is based on total systemic dose 
(AUC) and dose is sufficiently low that 
absorption and elimination rates are not 
severely saturated. In this case the total 
systemic dose (e.g., total mg dose) is the 
driver for the response, not the rate of 
uptake, and thus the most appropriate 
calculation of an IDLH yields an air 
concentration associated with achieving 
the total mass dose (mg) over the 30-min 
IDLH duration.
 ȣ If the underlying MOA is based on peak 
concentration, an IDLH based on oral 
gavage dosing regimen should ensure 
that the chemical-specific kinetics allow 
for rapid absorption in the GI tract (short 
Tmax). In this case, the peak concentration 
achieved from a 30-min exposure by 
either route is approximately equal.
 ȣ AUC or peak concentration is correct 
dose metric and the critical acute study is 
based on IV or IP injection data. Uptake is 
considered immediate and would parallel 
assumed rapid uptake via inhalation; 
thus, peak doses would be roughly similar 
across routes.
 • Moderate Concern:
 ȣ AUC is the correct dose metric and an 
oral dosing study was used. In most cases, 
since total dose is the driver for the onset 
of toxicity, use of the acute inhalation 
volume will be appropriate. An exception 
is the absorption or elimination rate is 
severely saturated, such that the orally 
administered dose does not represent 
well the total dose that would be received 
following an acute inhalation exposure 
at the IDLH. Under such conditions, the 
actual internal dose received by the test 
animals is lower than estimated by the 
administered oral dose, and the percentage 
of systemic bioavailability of the toxic form 
of the chemical (parent or metabolite) 
would need to be considered. Direct 
adjustment of the animal dose would be 
the best approach under these conditions. 
However, using some greater inhalation 
intake time to account for higher systemic 
doses across the two routes could also be 
considered in the absence of quantitative 
kinetic adjustments based on equivalent 
systemic doses across routes.
 ȣ Peak concentration is the correct dose 
metric and the chemical has slow 
Table E–1. Illustration of the impact of various inhaled air volumes on derived IDLH values 
Approach




Inhaled air volume 
(m3) UF*
Derived IDLH value†  
(mg/m3)
1994 Approach 50 70 10 100 3.5
IDLH Methodology 50 70 1.5 100 23.3
Abbreviation: IDLH = immediately dangerous to life or health; LD50 = median lethal dose; mg/kg = milligrams per kilograms of 
body weight; m3 = cubic meters; UF = uncertainty factor
*The UF of 100 is included as an example only and is not a default value used during the derivation of IDLH values  
based on oral data.
†Derived IDLH values were calculated with use of the following equation: IDLH value = [(Oral LD50 value * Body weight)/Inhaled 
Air Volume)]/(UF) 
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absorption kinetics in an oral gavage 
dosing study, or the critical oral study 
used serial dosing or continuous 
dosing protocols. In these cases the 
peak concentration in the critical 
study would not represent the likely 
peak concentration reached for the 
inhalation study, and the currently 
proposed extrapolation method would 
not necessarily be adequately protective. 
The toxicokinetic considerations for route-to-route 
extrapolation are complex. In most cases, because 
of the nature of the acute systemic effects involved 
in IDLH derivation, rapid absorption kinetics and 
rapid onset of effects are expected. Thus, under the 
most likely conditions, the 30-min inhalation volume 
of 1.5 m3 is viewed as an adequate default approach. 
However, there are scenarios based on chemical ki-
netics or non-inhalation study designs that may im-
pact the level of protection afforded by the default 
adjustment. For this reason, the IDLH methodol-
ogy has been modified to further communicate the 
potential conditions where additional kinetic-based 
adjustments may be needed. 
E.2  Time Scaling Adjustments 
In most cases IDLH values are derived from studies 
having exposures for periods shorter than or lon-
ger than 30 minutes. Thus, the PODs derived from 
such studies are adjusted to 30-minute-equivalent 
values. This adjustment is made by using the ten 
Berge et al. [1986] modification to Haber’s Rule that 
assumes the following relationship between con-
centration (Conc) and duration (time, t): (Concn × 
t = k). The impact of the value of n on the shape of 
the concentration–time–response curve is shown 
in Figures E–1 and E–2. As shown in these figures, 
larger values of n result in flatter curves, meaning 
that, for a given degree of toxicity, the concentra-
tion varies less with changes in duration. This is 
particularly apparent in Figure E–1, which shows 
the extrapolation from 4 hours to 30 minutes. This 
figure shows the impact of using different values of 
n to extrapolate to shorter durations from a con-
centration of 10 ppm at 4 hours. In this example, 
an n of 3 results in a concentration at 30 minutes 
that is not much higher than the test concentra-
tion at 4 hours, whereas the calculated concentra-
tion at 30 minutes is substantially higher when n = 
1. Thus, using n = 3 for extrapolating from longer 
durations to 30 minutes results in lower concentra-
tions, a more health-protective approach. 
Figure E–2 shows the converse situation, extrapo-
lating from an exposure to 10 ppm for 15 minutes 
to longer durations. In this case, the steeper curve 
associated with n = 1 results in a lower concentra-
tion at 30 minutes, compared with the value calcu-
lated using n = 3. Thus, using n = 1 is a more health-
protective approach in extrapolating from shorter 
durations to 30 minutes.
Based on these considerations, a default value of 
n = 1 is used for extrapolation from shorter dura-
tions, and a default value of n = 3 is used for ex-
trapolation from longer durations to the 30-minute 
duration of interest. In both cases, a calculated n 
specific to the chemical and species of interest is 
preferred when data are available to calculate the 
value. 
The data used to construct Figure E–1 are shown 
in Table E–2. Table E–2 shows the calculated con-
centrations when extrapolating from 10 ppm at 4 
hours, using n values of 1, 2, or 3.
The data used to construct Figure E–2 are shown in 
Table E–3. Table E–3 shows the calculated concen-
trations when extrapolating from 10 ppm at 0.25 
hours, using n values of 1, 2, or 3.
The following paragraph illustrates the effects of time 
scaling on inhalation toxicity data evaluated during 
the development of IDLH values for three chemicals: 
 • 1,1-Dimethylhydrazine (CAS# 57-41-7)
 • Vinyl acetate (CAS# 108-05-04)
 • Titanium tetrachloride (CAS# 7550-45-0). 
In the first example, the identified LC50 and LOAEL 
values for 1,1-dimethylhydrazine correlated to 
exposure durations of 5 or 15 minutes. No empir-
ically derived n values were identified within the 
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Figure E–2. ten Berge extrapolation from shorter (15 minute) to longer (30 minute) durations
Time (hours)

























Figure E–1. ten Berge Extrapolation from longer (4 hour) to shorter (30 minute) durations
*n = exponent applied within ten Berge equation [1986]
*n = exponent applied within ten Berge equation [1986]
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Table E–3. Time scaling for  
10 ppm at 15 minutes (0.25 hours)
Time n* = 1 n = 2 n = 3
0.25 10 10 10
0.5 5 7 8
1 3 5 6
1.5 2 4 6
2 1 4 5
2.5 1 3 5
3 1 3 4
3.5 1 3 4
4 1 3 4
n* = exponent applied within ten Berge equation [1986]
Table E–2. Time scaling for 10 ppm at 4 hours
Time, hours n* = 1 n = 2 n = 3
0.25 160 40 25
0.5 80 28 20
1 40 20 16
1.5 27 16 14
2 20 14 13
2.5 16 13 12
3 13 12 11
3.5 11 11 10
4 10 10 10
n* = exponent applied within ten Berge equation [1986]
reviewed literature for 1,1-dimethylhydrazine. 
Because the selected data were associated with 
exposure times less than 30 minutes, a default value 
of 1 for n within the ten Berge equation was applied 
on the basis of the rationale discussed in the previous 
paragraphs to extrapolate the most health-protective 
estimate. Time scaling resulted in a reduction of the 
exposure concentrations to approximately 17% to 
50% of the original exposure concentrations for the 
5- and 15-minute durations, respectively. Table E–4 
provides the extrapolated 30-minute-equivalent 
concentration for 1,1-dimethylhydrazine. Fig-
ure E–3 provides a visual representation of the 
data for 1,1-dimethylhydrazine. In comparison, 
the selected LC50 and LOAEL values for vinyl ac-
etate were associated with exposure durations of 2 
to 6 hours. Because no empirically derived value of 
n was available, a default value of 3 for n was used 
for time scaling in the ten Berge equation to adjust 
the data points from longer to shorter exposure du-
rations. As noted earlier, this is a health-protective 
default. The resulting extrapolated concentrations 
were approximately double the original exposure 
concentrations and can be found in Table E–5 and 
Figure E–4. The last example, titanium tetrachlo-
ride (see Table E–6 and Figure E–5), demonstrates 
the effects of the use of an empirically derived n 
to calculate the 30-minute equivalents for expo-
sure concentrations associated with durations both 
shorter and longer than 30 minutes. A value of 0.88 
has previously been calculated by the NAS during 
the development of the AEGL values for titanium 
tetrachloride [NAS 2007]. For data correspond-
ing to exposure durations less than 30 minutes, 
the resulting extrapolated concentrations were 
approximately 5% to 50% of the original LC50 and 
LOAEL values. Substantial changes in the extrapo-
lated 30-minute-equivalent concentrations were 
also observed when extrapolating from longer to 
shorter durations, with the relative increases being 
in a range of 2 to 10 times higher than the original 
value. As evident by the three previous examples, 
selection of the appropriate n during time scal-
ing may greatly affect the resulting 30-minute-
equivalent concentrations. 
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Table E–4. Time scaling of toxicity data from shorter to longer  
durations, using the ten Berge equation: 1,1-dimethylhydrazine (CAS# 57-41-7)
Study no. Species
Toxicological endpoint
Exposure duration  
(minute) n
30-minute equivalent value 
(ppm)




1  Rat 8,230 15 1 4,115
2  Rat 24,500 5 1 4,083
3  Dog 3,580 15 1 1,790
4  Dog 22,300 5 1 3,717
5  Dog 360 15 1 180
6  Dog 1,550 5 1 258
Abbreviations: LC50 value = median lethal concentration; LOAEL = lowest observed adverse effect level; ppm = parts per million; 























Figure E–3. Time scaling of toxicity data from shorter to longer durations, using the ten Berge 
equation: 1,1-dimethylhydrazine (CAS# 57-41-7)*
Abbreviation: ppm = parts per million
*All 30-minute data points are duration-adjusted values.
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Table E–5. Time scaling of toxicity data from shorter to longer durations,  

















1  Rat Bogdanffy et al. [1997] 1,000 360 3 2,289
2  Rat Roumiantsev et al. [1981] 3,238 240 3 6,476
3  Mouse Smyth and Carpenter [1973] 1,460 240 3 2,920
4  Dog Smyth and Carpenter [1973] 3,280 240 3 6,274
5  Guinea pig Smyth and Carpenter [1973] 5,210 240 3 10,420
Abbreviations: LC50 value = median lethal concentration; LOAEL = lowest observed adverse effect level; n = exponent applied in 


























Figure E–4. Time scaling of toxicity data from shorter to longer durations, using the ten Berge 
equation: vinyl acetate (CAS# 108-05-04)*
Abbreviation: ppm = parts per million
*All 30-minute data points are duration-adjusted values.
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Table E–6. Effects of an empirically-derived n on time adjustments,  















1  Rat Kelly [1980] 13,940 2 0.88 642
2  Rat Kelly [1980] 4600 5 0.88 600
3  Rat Kelly [1980] 713 15 0.88 324
4  Rat Kelly [1980] 171 60 0.88 376
5  Rat Kelly [1980] 143 120 0.88 691
6  Rat Kelly [1980] 59 240 0.88 627
7  Rat Gardner [1980] 26 20 0.88 16
Abbreviations: LC50 = statistically determined median concentration of a substance in the air that is estimated to cause death in 
50% (one half) of the test animals; LOAEL = lowest observed adverse effect level; n = exponent applied in ten Berge equation 

























Figure E–5. Effects of an empirically derived n on time adjustments, using the ten Berge equation: 
titanium tetrachloride (CAS# 7550-45-0)*
Abbreviation: ppm = parts per million. 
*All 30-minute data points are duration-adjusted values.
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